Nabriva Therapeutics (NBRVF) 10-K 17 Apr 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Feb. 28, 2023	Jun. 30, 2022
Document And Entity Information
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-37558
Entity Registrant Name	Nabriva Therapeutics plc
Entity Incorporation, State or Country Code	L2
Entity Address, Address Line One	Alexandra House, Office 225/227,
Entity Address, Address Line Two	The Sweepstakes
Entity Address, City or Town	Dublin 4
Entity Address, Country	IE
Entity Tax Identification Number	00-0000000
Entity Address, Postal Zip Code	00000
City Area Code	353 1
Local Phone Number	649 2000
Title of 12(b) Security	Ordinary Shares, nominal value $0.01 per share
Trading Symbol	NBRV
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 11.6
Entity Shares Outstanding		3,201,456
Auditor Name	KPMG LLP
Auditor Firm ID	185
Auditor Location	Philadelphia, Pennsylvania
Entity Central Index Key	0001641640
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 12,414	$ 47,659
Restricted cash	123	175
Short-term investments		16
Accounts receivable, net and other receivables	6,742	12,751
Inventory	9,676	14,509
Prepaid expenses	2,149	5,155
Total current assets	31,104	80,265
Property and equipment, net	280	233
Intangible assets, net	3	31
Other non-current assets	378	380
Total assets	31,765	80,909
Current liabilities:
Current portion of long-term debt	4,833	3,765
Accounts payable	5,431	4,372
Accrued expense and other current liabilities	17,341	13,829
Deferred revenue		374
Total current liabilities	27,605	22,340
Non-current liabilities:
Long-term debt	388	4,265
Other non-current liabilities	479	954
Total non-current liabilities	867	5,219
Total liabilities	28,472	27,559
Commitments and contingencies (Note 15)
Stockholders' equity:
Ordinary shares, nominal value $0.01, 12,000,000 ordinary shares authorized at December 31, 2022; 3,201,417 and 2,268,612 issued and outstanding at December 31, 2022 and December 31, 2021, respectively	32	23
Preferred shares, nominal value $0.01, 100,000,000 shares authorized at December 31, 2022; None issued and outstanding
Additional paid in capital	656,095	648,976
Accumulated other comprehensive income	27	27
Accumulated deficit	(652,861)	(595,676)
Total stockholders' equity	3,293	53,350
Total liabilities and stockholders' equity	$ 31,765	$ 80,909

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Consolidated Balance Sheets
Ordinary stock, nominal value (in dollars per share)	$ 0.01	$ 0.01
Ordinary stock, authorized shares	12,000,000	12,000,000
Ordinary stock, issued shares	3,201,417	2,268,612
Ordinary stock, outstanding shares	3,201,417	2,268,612
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized shares	100,000,000	100,000,000
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Total revenues	$ 36,935	$ 28,895	$ 5,027
Operating expenses:
Cost of revenues	(28,581)	(13,148)	(766)
Loss on inventory commitments	(4,317)
Research and development expenses	(14,263)	(12,630)	(15,102)
Selling, general and administrative expenses	(45,264)	(51,645)	(55,285)
Total operating expenses	(92,425)	(77,423)	(71,153)
Loss from operations	(55,490)	(48,528)	(66,126)
Other income (expense):
Other income, net	571	469	1,187
Interest expense, net	(698)	(901)	(1,649)
Loss on extinguishment of debt			(2,757)
Loss before income taxes	(55,617)	(48,960)	(69,345)
Income tax expense	(1,568)	(490)	(139)
Net loss	$ (57,185)	$ (49,450)	$ (69,484)
Loss per share
Basic loss ($ per share)	$ (21.32)	$ (28.52)	$ (135.23)
Diluted loss ($ per share)	$ (21.32)	$ (28.52)	$ (135.23)
Weighted average number of shares:
Basic (in shares)	2,681,968	1,733,978	513,804
Diluted (in shares)	2,681,968	1,733,978	513,804
Product revenue, net
Revenues:
Total revenues	$ 34,742	$ 23,386	$ 108
Collaboration revenue
Revenues:
Total revenues	926	3,830	2,756
Research premium and grant revenue
Revenues:
Total revenues	$ 1,267	$ 1,679	$ 2,163

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($) shares in Thousands, $ in Thousands	Common stock/Ordinary shares	Additional paid in capital	Accumulated other comprehensive income	Accumulated deficit	Total
Stockholders' equity, beginning balance at Dec. 31, 2019	$ 4	$ 517,985	$ 27	$ (476,742)	$ 41,274
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2019	378
Consolidated Statements of Changes in Stockholders' Equity (Deficit)
Issuance of ordinary shares	$ 4	61,056			61,060
Issuance of ordinary shares (in shares)	463
Shares issued in connection with the employee stock purchase plan		43			43
Shares issued in connection with the vesting of restricted stock units (in shares)	2
Equity transaction costs		(4,977)			(4,977)
Stock-based compensation expense		5,219			5,219
Net loss				(69,484)	(69,484)
Stockholders' equity, ending balance at Dec. 31, 2020	$ 8	579,326	27	(546,226)	33,135
Stockholders' equity, ending balance (in shares) at Dec. 31, 2020	843
Consolidated Statements of Changes in Stockholders' Equity (Deficit)
Issuance of ordinary shares	$ 15	70,123			70,138
Issuance of ordinary shares (in shares)	1,398
Shares issued in connection with the vesting of restricted stock units		2			2
Shares issued in connection with the vesting of restricted stock units (in shares)	3
Equity transaction costs		(3,766)			(3,766)
Equity transaction costs (in shares)	25
Stock-based compensation expense		3,291			3,291
Net loss				(49,450)	(49,450)
Stockholders' equity, ending balance at Dec. 31, 2021	$ 23	648,976	27	(595,676)	53,350
Stockholders' equity, ending balance (in shares) at Dec. 31, 2021	2,269
Consolidated Statements of Changes in Stockholders' Equity (Deficit)
Issuance of ordinary shares	$ 9	5,575			5,584
Issuance of ordinary shares (in shares)	924
Shares issued in connection with the vesting of restricted stock units		1			1
Shares issued in connection with the vesting of restricted stock units (in shares)	8
Equity transaction costs		(333)			(333)
Stock-based compensation expense		1,876			1,876
Net loss				(57,185)	(57,185)
Stockholders' equity, ending balance at Dec. 31, 2022	$ 32	$ 656,095	$ 27	$ (652,861)	$ 3,293
Stockholders' equity, ending balance (in shares) at Dec. 31, 2022	3,201

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (57,185)	$ (49,450)	$ (69,484)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash other income, net	43	424	50
Non-cash interest expense	363	404	636
Loss on extinguishment of debt			2,757
Loss on inventory commitments	4,317
Depreciation and amortization expense	217	356	417
Amortization of right-of-use assets		281	403
Stock-based compensation	1,967	3,291	5,219
Other	(166)	(6)	62
Changes in operating assets and liabilities:
(Increase) decrease in other non-current assets	2	(10)	8
(Increase) decrease in accounts receivable, net and other receivables and prepaid expenses	9,015	(8,117)	(5,887)
(Increase) decrease in inventory	4,833	(8,686)	(5,141)
Increase (decrease) in accounts payable	1,093	1,581	(1,813)
Increase in accrued expenses and other liabilities	(1,147)	946	714
Increase (decrease) in deferred revenue	(374)	(376)	750
Decrease in other non-current liabilities	(69)	(189)	(2)
Increase (decrease) in income tax liabilities	380	(6)	(20)
Net cash used in operating activities	(36,711)	(59,557)	(71,331)
Cash flows from investing activities
Purchases of equipment and intangible assets	(211)	(25)	(113)
Other	(52)	(56)	(161)
Net cash used in investing activities	(263)	(81)	(274)
Cash flows from financing activities
Proceeds from exercise of warrants			665
Proceeds from issuance of ordinary shares and warrants	2,123	27,911	53,460
Proceeds from at-the-market facility	3,460	42,280	7,520
Proceeds from employee stock purchase plan			43
Repayments of long-term borrowings	(2,921)		(30,000)
Repayments of warrants	(406)
Equity transaction costs	(405)	(3,825)	(4,764)
Net cash provided by financing activities	1,851	66,366	26,924
Effects of exchange rate changes on the balance of cash held in foreign currencies	(174)	(484)	(140)
Net increase/(decrease) in cash, cash equivalents and restricted cash	(35,297)	6,244	(44,821)
Cash, cash equivalents, and restricted cash at beginning of year	47,834	41,590	86,411
Cash, cash equivalents and restricted cash at end of year	12,537	47,834	41,590
Supplemental disclosure of cash flow information:
Interest paid	406	497	1,396
Taxes paid	1,000	513	4
Equity transaction costs included in accounts payable and accrued expenses	$ 640	$ 712	$ 765

Organization and Business Activ

Organization and Business Activities	12 Months Ended
	Dec. 31, 2022
Organization and Business Activities
Organization and Business Activities	1. Organization and Business Activities Nabriva Therapeutics plc, or Nabriva Ireland, together with its wholly owned and consolidated subsidiaries, Nabriva Therapeutics GmbH, or Nabriva Austria, Nabriva Therapeutics US, Inc., Zavante Therapeutics, Inc., or Zavante, and Nabriva Therapeutics Ireland DAC, collectively, Nabriva, or the Company, is a biopharmaceutical company that historically engaged in the commercialization and research and development of novel anti-infective agents to treat serious infections. The Company has the commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. The Company’s headquarters are located at Alexandra House, Office 225/227, The Sweepstakes, Dublin 4, Ireland. As part of a plan approved by its board of directors on January 4, 2023 to preserve its cash to adequately fund an orderly wind down of its operations, or the Cash Preservation Plan, the Company has reduced its operations to those necessary to: (i) make SIVEXTRO and XENLETA commercially available to wholesale customers; (ii) identify and explore, with the assistance of Torreya Capital, a range of strategic options, including the sale, license or other disposition of one or more of its assets, technologies or products, including XENLETA and CONTEPO; and (iii) wind down its business. The Company has no intention of resuming any active sales promotion or research and development activities. Also as part of the Cash Preservation Plan, the Company’s board of directors determined to terminate all of the Company’s employees not deemed necessary to execute an orderly wind down of the Company’s operations. ​ In January 2023, the Company settled all outstanding balances due to Hercules Capital, Inc., or Hercules, and removed all secured liens on all of its assets. The Company also terminated its agreement with Amplity Health, the contract sales organization responsible for promoting SIVEXTRO and XENLETA and, on January 31, 2023, entered into a letter agreement, or the Letter Agreement, relating to the Company’s Sales Promotion and Distribution Agreement, or the Distribution Agreement, with MSD International GmbH, or MSD, and Merck Sharp & Dohme Corp., or the Supplier, to begin transition responsibility for the promotion and distribution of SIVEXTRO back to Merck & Co. Inc., or Merck, as of June 30, 2023. Although the Company has ceased its active commercialization efforts, the Company expects to continue to make XENLETA and, for the remaining term of the Distribution Agreement, SIVEXTRO commercially available to wholesale customers. ​ The Company has retained Torreya Capital to advise on its exploration of a range of strategic options. While the Company continues to work with Torreya Capital on identifying and evaluating potential strategic options with the goal of maximizing value, the Company is currently focused, as part of its Cash Preservation Plan, on the sale of its existing assets, including XENLETA and CONTEPO. In the event that the Company’s board of directors determines that a liquidation and dissolution of the Company’s business approved by shareholders is the best method to maximize shareholder value, the Company would file proxy materials with the Securities and Exchange Commission and schedule an extraordinary meeting of its shareholders to seek approval of such a plan as required. Liquidity The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40 , Presentation of Financial Statements Going Concern Since its inception, the Company has incurred net losses and generated negative cash flows from its operations which has resulted in a significant accumulated deficit to date. The Company has financed its operations through the sale of equity securities, convertible and term debt financings and research and development support from governmental grants and proceeds from its licensing agreements. As of December 31, 2022, the Company had cash and cash equivalents and restricted cash of $12.5 million. In connection with the Company’s assessment of going concern, management has determined the Company’s liquidity condition and its existing financial obligations raise substantial doubt about the Company’s ability to continue as a going concern one year from the date that these financial statements are filed, if it does not monetize of at least one of the Company’s assets. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. The Company aims to complete an asset monetization deal; however, completing an asset monetization is not entirely within the Company’s control. Therefore, the Company may not have sufficient cash flows to fund its operations for the next twelve months after the date the consolidated financial statements are issued and therefore, management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. While the Company has raised capital in the past, the ability to raise capital in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future capital raises in their assessment of the Company’s ability to meet its obligations for the next twelve months. In May 2021, the Company entered into an Open Market Sale Agreement, or the Sale Agreement, with Jefferies, LLC, or Jefferies as agent, pursuant to which the Company may offer and sell ordinary shares, for aggregate gross sale proceeds of up to $50.0 million, from time to time through Jefferies, by any method permitted that is deemed an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. As of December 31, 2022, the Company has issued and sold an aggregate of 1,429,729 ordinary shares pursuant to the Sale Agreement and received gross proceeds of $33.9 million and net proceeds of $32.5 million, after deducting commissions to Jefferies and other offering expenses. From January 1, 2023 and through the date of this filing, the Company did not sell any shares under the Sale Agreement. In September 2021, the Company entered into a purchase agreement, or Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which, subject to the terms and conditions, provides that the Company has the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $23.0 million of its ordinary shares. In addition, under the Purchase Agreement, the Company agreed to issue a commitment fee of 25,298 ordinary shares, or the Commitment Shares, as consideration for Lincoln Park entering into the Purchase Agreement and for the payment of $0.01 per Commitment Share. Under the Purchase Agreement, the Company may from time to time, at its discretion, direct Lincoln Park to purchase on any single business day, or a Regular Purchase, up to (i) 16,000 ordinary shares if the closing sale price of its ordinary shares is not below $0.25 per share on Nasdaq, (ii) 24,000 ordinary shares if the closing sale price of its ordinary shares is not below $50.00 per share on Nasdaq or (iii) 32,000 ordinary shares if the closing sale price of its ordinary shares is not below $75.00 per share on Nasdaq. In addition to Regular Purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases on the terms and subject to the conditions set forth in the Purchase Agreement. In any case, Lincoln Park’s commitment in any single Regular Purchase may not exceed $2.5 million absent a mutual agreement to increase such amount. As of December 31, 2022, the Company has issued and sold an aggregate of 320,000 ordinary shares pursuant to the Purchase Agreement and received net proceeds of $4.6 million. From January 1, 2023 and through the date of this filing, the Company did not sell any shares under the Purchase Agreement. As of the date of this filing, the Company may issue and sell ordinary shares for gross proceeds of up to $18.5 million under the Purchase Agreement, subject to the Nasdaq rules which may limit the Company’s ability to make sales of its ordinary shares to Lincoln Park in excess of a specified amount without prior shareholder approval. Based on its current operating plans, the Company expects that its existing cash, cash equivalents and restricted cash and short-term investments as of the date of this filing will be sufficient to enable the Company to fund its operating expenses into at least June 2023. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its capital resources sooner than expected. This estimate assumes, among other things, that the Company does not obtain any additional funding through grants and clinical trial support or collaboration agreements

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Preparation The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or US GAAP, and SEC regulations for annual reporting. The consolidated financial statements include the accounts of Nabriva Therapeutics plc and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Reverse Stock Split On September 16, 2022, the Company filed an Amended and Restated Memorandum and Articles of Association of the Company with the Irish Companies Registration Office and effected, a one twenty five Functional Currency Transactions and Balances In preparing the consolidated financial statements, transactions in currencies other than the U.S. dollar are recognized at the exchange rates prevailing at the dates of the transactions. Foreign currency exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statements of operations. Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. Cash as of December 31, 2022 solely consisted of deposits at banking institutions, which may exceed Federal Deposit Insurance Corporation insured limits. Short-term Investments The Company has designated its investments in securities as available-for-sale securities and measures these securities at their respective fair values. Investments that mature in one year or less are classified as short-term available-for-sale securities. Investments that are not considered available for use in current operations are classified as long-term available-for-sale securities. Changes in the fair value of available-for-sale investments are recognized in other comprehensive income (loss). Inventory ​ Inventory is stated at the lower of cost or net realizable value. Inventory is valued on a first-in, first-out basis and consists primarily of material costs, third-party manufacturing costs, and related transportation costs along the Company's supply chain. The Company capitalizes inventory upon regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are recorded as research and development expense. Costs of drug product to be consumed in any current or future clinical trials will continue to be recognized as research and development expense and costs of sample inventory is recorded as selling, general and administrative expense. The Company reviews inventories for realization on a quarterly basis and records provisions for estimated excess, slow-moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value when necessary. ​ The components of our inventory at December 31, 2022 and 2021 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ As of ​ December 31, ​ ​ December 31, (in thousands) ​ 2022 ​ ​ 2021 XENLETA raw materials $ 916 ​ $ 1,528 XENLETA work in process 4,658 ​ 9,142 XENLETA finished goods ​ 640 ​ ​ 18 Total XENLETA ​ 6,214 ​ ​ 10,688 SIVEXTRO finished goods 3,462 ​ 3,821 Total inventory $ 9,676 ​ $ 14,509 ​ As of December 31, 2022, the Company has $0.9 million of prepaid inventory of XENLETA included in prepaid expenses in the consolidated balance sheet. As a result of the Company’s intention to wind down operations, the Company made an assessment of the net realizable value of XENLETA inventory as of December 31, 2022, based mainly on the potential to monetize any inventory that may be included in an asset sale of XENLETA. The Company will continue to make XENLETA commercially available in the US during the transition period as the Company prepares to wind down operations. In conjunction with XENLETA, the Company adjusted the value of inventory and prepaid inventory as of December 31, 2022 with an adjustment of $5.6 million. The Company is in ongoing discussions to sell the product rights of XENLETA, its related inventory, and potentially assign certain contractual commitments. ​ Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property and equipment are as follows: 3 5 3 Intangible Assets and Other Long-lived Assets Intangible assets, such as acquired computer software licenses, are capitalized on the basis of the costs incurred to acquire the software and bring it into use. These costs are amortized on a straight-line basis over their estimated useful lives ( 3 Long-lived assets are assessed for potential impairment when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. An impairment loss would be recognized when undiscounted cash flows expected to be generated by an asset, is less than its carrying amount. The impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value and recognized in these financial statements. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating segment, which is the commercialization and development of novel anti-infective agents to treat serious and life-threatening infections. Revenue Recognition Revenue from Contracts with Customers Net Product Revenue In September 2019, the Company launched XENLETA and in April 2021 the Company began exclusive distribution of SIVEXTRO in the United States and certain of its territories. The Company sells its products principally to a limited number of specialty distributors and wholesalers. The Company recognizes revenue once it has transferred physical possession of the goods and the customer obtains legal title to the product. Payment terms between Nabriva and its customers are generally approximately 60 days from the invoice date. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of its product. The transaction price that the Company recognizes as revenue reflects the amount it expects to be entitled to in connection with the sale and transfer of control of product to its customers. At the time that the Company’s customers take control of the product, which is when the Company’s performance obligation under the sales contracts is complete, the Company records product revenues net of applicable reserves for various types of variable consideration. The types of variable consideration are as follows: ● fees-for-service; ● product returns; ● chargebacks and rebates; ● government rebates; ● commercial payer and other rebates; ● Group Purchasing Organizations, or GPO, administration fees; and ● voluntary patient assistance programs. In determining the amounts of certain allowances and accruals, the Company must make significant judgments and estimates. For example, in determining these amounts, the Company estimates prescription demand from retail pharmacies, specialty pharmacies, hospital demand, buying patterns by hospitals, hospital systems and/or group purchasing organizations and the levels of inventory held by distributors and customers. The Company also analyzes third party end usage product consumption patterns to gauge demand for its products. Making these determinations involves analyzing third party industry data to determine whether trends in historical channel distribution patterns will predict future product sales. The Company receives data periodically from its customers on inventory levels and historical channel sales mix, and the Company considers this data when determining the amount of the allowances and accruals for variable consideration. In assessing the amount of net revenue to record, the Company considers both the likelihood and the magnitude of the revenue reversal. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. The specific considerations the Company uses in estimating these amounts related to variable consideration associated with the Company’s products are as follows: Fees-for-service does not consider the fees separate from the distributors’ purchase of the product. The Company records its fee-for-service accruals based on distributors’ purchases and the applicable discount rate. Product returns history of SIVEXTRO and XENLETA returns, the Company estimated returns based on industry data for comparable products in the market. As the Company distributes its product and establishes historical sales over a longer period of time, the Company will be able to place more reliance on historical purchasing, demand and return patterns of its customers when evaluating its reserves for product returns. The Company’s XENLETA product has a forty-eight month shelf life and SIVEXTRO has a thirty-six month shelf life. The Company’s customers also have the right to return excess inventory on new products that do not yield forecasted sales. To the extent the Company’s customers determine that the quantities they purchased are in excess of their customers demand, product returns could increase in excess of what the Company has currently reserved which would result in a reduction to net revenues in future periods. ​ At the end of each reporting period for any of its products, the Company may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of product currently being shipped, price changes of competitive products and introductions of generic products. Chargebacks and rebates Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, p ublic h ealth s ervice institutions, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company’s wholesalers or specialty distributors. Contracted customers generally purchase the product at a discounted price. The Company provides a credit to its wholesaler or specialty distributor customers (i.e., chargeback), representing the difference between the customer’s acquisition list price and the discounted price. The calculation of the accrual for chargebacks and rebates is based on estimates of claims and their associated cost that the Company expects to receive associated with product sales that have been recognized as revenue but remain in the distribution channel as inventory at the end of each reporting period. Government rebates –The Company is subject to discount obligations primarily under state Medicaid and Medicare programs. The Company estimates its Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payer mix. These reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The calculation of the accrual for government rebates is based on estimates of claims and their associated cost that the Company expects to receive associated with product sales that have been recognized as revenue but remain in the distribution channel as inventory at the end of each reporting period. Commercial payer and other rebates cost that the Company expects to receive associated with product sales that have been recognized as revenue but remain in the distribution channel as inventory at the end of each reporting period. GPO administration fees – The Company contracts with GPOs and pays administration fees related to contacting and membership management services provided. In assessing if the consideration paid to the GPO should be recorded as a reduction in the transaction price, the Company determines whether the payment is for a distinct good or service or a combination of both. Since GPO fees are not specifically identifiable, the Company does not consider the fees separate from the purchase of the product. Additionally, the GPO services generally cannot be provided by a third party. Because of these factors, the consideration paid is considered a reduction of revenue. Patient assistance At the end of each reporting period, the Company will adjust its variable consideration estimates for product returns, chargebacks, and rebates when the Company believes actual experience may differ from current estimates. Cost of Revenues Cost of revenues for XENLETA primarily represents direct and indirect manufacturing costs, while cost of revenues for SIVEXTRO represent the actual purchase cost for the finished product from Merck. For the years ended December 31, 2022 and 2021, cost of revenues include a $5.2 million and $0.3 million non-cash charge for the net realizable value of inventory related to the potential asset sale of XENLETA ​ Research Premium and Grant Revenue Grant revenue comprises (a) the research premium from the Austrian government, (b) grants received from the Austrian Research Promotion Agency ( Österreichische Forschungsförderungsgesellschaft, or FFG The research premium the Company receives from the Austrian government is calculated at a specified percent of specified research and development cost base. The Company recognizes the research premium as long as it has incurred research and development expenses. All grants are non-refundable as long as the conditions of the grant are met. Nabriva is and has been in full compliance with the conditions of the grants and all related regulations. Research and Development Expenses All research and development costs are expensed as incurred. Research and development costs included direct personnel and material costs, related overheads, depreciation of equipment used for research or development purposes; costs for clinical research; costs for the utilization of third parties’ patents for research and development purposes and other taxes related to research facilities. Share-based Payments The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award in accordance with ASC 718, Compensation — Stock Compensation fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Leases The Company follows ASC Topic 842, Leases The Company determines if an arrangement is a lease at inception. Operating lease right-of-use, or ROU, assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the remaining lease term. ROU assets are included in property and equipment, and operating lease liabilities are included in accrued expenses on the Company’s consolidated balance sheet. The Company has elected not to recognize ROU assets or lease liabilities for short-term leases. Since none of the Company’s lease agreements provide an implicit rate, the Company estimates an incremental borrowing rate over the lease term in determining the present value of lease payments. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as operating costs and property taxes are expensed as incurred. Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. In recognizing the benefit of tax positions, the Company has taken or expects to take, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company’s policy is to record interest and penalties related to tax matters in income tax expense. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company has not adopted any new accounting pronouncements for the year ended December 31, 2022, nor are there any recently issued accounting pronouncements that are expected to have a material impact on the Company´s consolidated financial statements in future periods.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2022
Fair Value Measurement
Fair Value Measurement	3. Fair Value Measurement US GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: ● Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. ● Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (as exchange rates). ● Level 3: Valuation techniques that include inputs for the asset or liability that are not based on observable market data (those are unobservable inputs) and significant to the overall fair value measurement. The following table presents the financial instruments measured at fair value and classified by level according to the fair value measurement hierarchy: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Total December 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalent: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market fund ​ $ — ​ $ — ​ $ — $ — Total assets ​ $ — ​ $ — ​ $ — $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Total December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalent: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market fund ​ $ 8,050 ​ $ — ​ $ — $ 8,050 Short-term investments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Term deposits ​ 16 ​ — ​ — ​ 16 Total assets ​ $ 8,066 ​ $ — ​ $ — $ 8,066 ​ There were no transfers between levels in the years ended December 31, 2022 and 2021. There were no changes in valuation techniques during the years ended December 31, 2022 and 2021. As of December 31, 2022 and 2021, the Company did not hold any financial instruments as liabilities that were held at fair value. The Company believes that the carrying value of its long-term debt approximates fair value based on current interest rates. Receivables and accounts payable are carried at their historical cost which approximates fair value due to their short-term nature.

Accounts Receivable, net and Ot

Accounts Receivable, net and Other Receivables	12 Months Ended
	Dec. 31, 2022
Accounts Receivable, net and Other Receivables
Accounts Receivable, net and Other Receivables	4. Accounts Receivable, net and Other Receivables ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31 (in thousands) 2022 2021 Receivables from customers, net ​ $ 3,208 ​ $ 8,778 Receivables from collaborative arrangements ​ ​ 274 ​ ​ 2,193 Research premium ​ ​ 2,472 ​ ​ 1,237 Other receivables ​ 788 ​ 543 Total accounts receivable, net and other receivables ​ $ 6,742 ​ $ 12,751 ​ The following table summarizes balances and activity of product revenue allowances and reserves: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ ​ 2022 ​ 2021 Receivables from customers ​ $ 5,168 ​ $ 10,149 Less: fee for service ​ (832) ​ (924) Less: chargeback reserve ​ (902) ​ (249) Less: cash discount ​ (226) ​ (198) Receivables from customers, net ​ $ 3,208 ​ $ 8,778 ​

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2022
Property and Equipment
Property and Equipment	5. Property and Equipment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31 (in thousands) 2022 2021 IT equipment ​ $ 1,095 ​ $ 1,083 Laboratory equipment ​ 3,604 ​ 3,404 Other equipment ​ 100 ​ 101 ​ ​ ​ 4,799 ​ ​ 4,588 Less: Accumulated depreciation ​ ​ (4,519) ​ ​ (4,355) Property and equipment, net ​ $ 280 ​ $ 233 ​

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2022
Accrued Expenses and Other Current Liabilities
Accrued Expenses and Other Current Liabilities	6. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities include the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31 (in thousands) ​ 2022 ​ ​ 2021 Research and development related costs ​ $ 707 ​ $ 789 Payroll and related costs ​ 1,737 ​ 5,085 Accounting, tax and audit services ​ 552 ​ 736 Manufacturing and inventory ​ ​ 8,113 ​ ​ 592 Product returns ​ ​ 784 ​ ​ 2,282 Government rebates ​ ​ 2,028 ​ ​ 1,751 Other accrued gross to net ​ ​ 2,129 ​ ​ 1,090 Other ​ 1,291 ​ 1,504 Total accrued expenses and other current liabilities ​ $ 17,341 ​ $ 13,829 ​ As of December 31, 2022, accrued manufacturing and inventory includes a $4.3 million provision for the potential loss on some existing commitments and contingencies. The purchase obligations may be mitigated through the use of commercially reasonable efforts to reallocate resources to other projects should the Company provide adequate notice in advance of any annual commitments. Additionally, as part of the asset sale process some of the other contractual commitments may be transferred as part of any potential transaction. Product return activity during the years ended December 31, 2022, 2021 and 2020 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 ​ 2020 Balance at January 1 ​ $ 2,282 ​ $ 349 ​ $ 33 Provision recorded during the period ​ 526 ​ 2,043 ​ 431 Credits issued during the period ​ (2,024) ​ ​ (110) ​ ​ (115) Balance at December 31 ​ $ 784 ​ $ 2,282 ​ $ 349 ​

Debt

Debt	12 Months Ended
	Dec. 31, 2022
Debt
Debt	7. Debt In December 2018, the Company entered into the Loan Agreement by and among the Company, Nabriva Therapeutics Ireland DAC, and certain other subsidiaries of the Company and Hercules Capital, Inc., or Hercules, pursuant to which a term loan of up to an aggregate principal amount of $75.0 million was available to the Company. The Loan Agreement initially provided for an initial term loan advance of $25.0 million, which was funded in December 2018, and, at the Company’s option and subject to the occurrence of certain funding conditions, several additional tranches of which $10.0 million became available upon the approval by the FDA of the NDA for XENLETA, which was drawn down. Prior to repayment, the term loan bore interest at an annual rate equal to the greater of 9.80% or 9.80% plus the prime rate of interest minus 5.50%. Effective September 22, 2022 the prime rate increased to 6.25%, which increased the interest on the loan with Hercules to 10.55%. The Loan Agreement provided for interest-only payments through July 1, 2021 and repayment of the outstanding principal balance of the term loan thereafter in monthly installments through June 1, 2023, or the Maturity Date. In addition, the Company was required to pay a fee of 6.95% of the aggregate amount of advances under the Loan Agreement at the Maturity Date, or the End of Term Fee. At the Company’s option, the Company was entitled to elect to prepay any portion of the outstanding term loan that is greater than or equal to $5.0 million by paying such portion of the principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid, or the Prepayment Fee: (i) 3.0% if the term loan was prepaid during the first 12 months following the initial closing, (ii) 2.0% if the term loan was prepaid after 12 months following the initial closing but before 24 months following the initial closing and (iii) 1.0% if the term loan was prepaid any time thereafter but prior to the Maturity Date. On March 11, 2020, the Company entered into an amendment, or the Third Amendment, to its Loan Agreement with Hercules. Pursuant to the Third Amendment, the Company repaid $30.0 million of the $35.0 million in aggregate principal amount of debt outstanding under the Loan Agreement, or the Prepayment. The Company determined to enter into the Third Amendment following the effectiveness of a performance covenant in February 2020 under which it became obligated to either (1) achieve 80% of its net product revenue sales target over a trailing six-month period, or (2) maintain an amount of cash and cash equivalents in accounts pledged to Hercules plus a specified amount of eligible accounts receivables equal to the greater of the amount outstanding under the Loan Agreement or $40.0 million. Under the Third Amendment, the Company and Hercules agreed to defer the end of term loan charge payment of $2.1 million that would have otherwise become payable on the date of the Prepayment and to reduce the Prepayment Fee with respect to the Prepayment from $600,000 to $300,000 and to defer its payment, in each case, until June 1, 2023 or such earlier date on which all loans under the Loan Agreement were repaid or become due and payable. The Third Amendment also reset the revenue performance covenant to 70% of targeted revenue based on a revised net product revenue forecast and lowered the minimum liquidity requirement to $3.0 million in cash and cash equivalents, in each case, following the Prepayment. The new minimum liquidity requirement would not have applied if CONTEPO received regulatory approval from the FDA and the Company achieved at least 70% of its revised net product revenue targets under the Loan Agreement. On June 2, 2021, the Company entered into a further amendment, or the Fourth Amendment, to its Loan and Security Agreement with Hercules. Pursuant to the Fourth Amendment, the date on which the Company was required to commence repaying principal under the Loan Agreement was extended to April 1, 2022. The Company began making interest and principal payments in April 2022. In addition, pursuant to the Fourth Amendment, the minimum liquidity requirement of $3.0 million in cash and cash equivalents would have been waived at any time the Company had recognized $15.0 million of net product revenue during the applicable trailing three months. ​ On January 5, 2023 the Company repaid $4.5 million to Hercules Capital, including principal, accrued and unpaid interest, fees and other expenses, under its loan agreement. Effective at the time of repayment, the Hercules loan agreement was terminated, and Hercules released all security interests held on the assets of the Company and its subsidiaries. ​ Long-term debt as December 31, 2022 and 2021 consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ As of ​ ​ ​ December 31, ​ ​ December 31, (in thousands) ​ 2022 ​ 2021 Term loan payable $ 2,079 $ 5,000 End of term fee ​ ​ 2,615 ​ ​ 2,331 Unamortized debt issuance costs ​ (55) ​ (145) Carrying value of term loan ​ ​ 4,639 ​ ​ 7,186 Other debt ​ ​ 582 ​ ​ 844 Less: Amounts due within one year ​ ​ (4,833) ​ ​ (3,765) Total long-term debt $ 388 $ 4,265 ​ As of December 31, 2022, the maturities of the Company’s long-term debt were as follows: ​ ​ ​ ​ ​ (in thousands) ​ ​ ​ 2023 ​ $ 5,006 2024 ​ $ 194 2025 ​ $ 194 ​

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity
Stockholders' Equity	8. Stockholders’ Equity In September 2021, the Company entered into a purchase agreement, or Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which, subject to the terms and conditions, provides that the Company has the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $23.0 million of its ordinary shares. In addition, under the Purchase Agreement, the Company agreed to issue a commitment fee of 25,298 ordinary shares, or the Commitment Shares, as consideration for Lincoln Park entering into the Purchase Agreement and for the payment of $0.01 per Commitment Share. Under the Purchase Agreement, the Company may from time to time, at its discretion, direct Lincoln Park to purchase on any single business day, or a Regular Purchase, up to (i) 16,000 ordinary shares if the closing sale price of the Company’sordinary shares is not below $0.25 per share on Nasdaq, (ii) 24,000 ordinary shares if the closing sale price of the Company’s ordinary shares is not below $50.00 per share on Nasdaq or (iii) 32,000 ordinary shares if the closing sale price of the Company’s ordinary shares is not below $75.00 per share on Nasdaq. In addition to Regular Purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases on the terms and subject to the conditions set forth in the Purchase Agreement. Notwithstanding the foregoing, the Company may direct Lincoln Park to purchase on any single business day ordinary shares with a purchase price equal to or greater than $200,000 irrespective of the number of ordinary shares required to approximate that amount. In any case, Lincoln Park’s commitment in any single Regular Purchase may not exceed $2.5 million absent a mutual agreement to increase such amount. As of December 31, 2022, the Company has issued and sold an aggregate of 320,000 ordinary shares pursuant to the Purchase Agreement and received net proceeds of $4.6 million. From January 1, 2023 and through the date of this filing, the Company did not sell any shares under the Purchase Agreement. As of the date of this filing, the Company may issue and sell ordinary shares for gross proceeds of up to $18.5 million under the Purchase Agreement, subject to the Nasdaq rules which may limit its ability to make sales of its ordinary shares to Lincoln Park in excess of a specified amount without prior shareholder approval. ​ In May 2021, the Company entered into an Open Market Sale Agreement SM In March 2021, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which it agreed to issue and sell in a registered direct offering (1) an aggregate of 390,440 ordinary shares, $0.01 nominal value per share, and accompanying warrants to purchase up to an aggregate of 195,220 ordinary shares and (2) pre-funded warrants to purchase up to an aggregate of 24,000 ordinary shares and accompanying ordinary share warrants to purchase up to an aggregate of 12,000 ordinary shares. Each share was issued and sold together with an accompanying ordinary share warrant at a combined price of $61.31, and each pre-funded warrant was issued and sold together with an accompanying ordinary share warrant at a combined price of $61.06. The proceeds from the offering were $25.4 million gross and $23.4 million net after deducting the placement agent’s fees and estimated offering expenses. Each pre-funded warrant had an exercise price per ordinary share equal to $0.01 and each pre-funded warrant was exercised in full on the issuance date. Each ordinary share warrant has an exercise price per ordinary share equal to $59.75, was exercisable on the date of issuance and will expire on the five-year anniversary of the date of issuance. ​ In May 2020, the Company entered into a securities purchase agreement with certain institutional investors, including Fidelity Management & Research Company, LLC pursuant to which the Company issued and sold in a registered direct offering an aggregate of 165,755 ordinary shares and accompanying warrants to purchase up to an aggregate of 165,755 ordinary shares. Each share the Company issued and sold together with an accompanying warrant at a combined price of $229.21. The proceeds to the Company from the offering were $38.0 million gross and $35.2 million net, after deducting the placement agent’s fees and other offering expenses. Each warrant was immediately exercisable and will expire on the two-year anniversary of the issuance date. As of December 31, 2022, there were no warrants outstanding. ​

Revenue

Revenue	12 Months Ended
	Dec. 31, 2022
Revenue
Revenues	9. Revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, (in thousands) 2022 2021 2020 Product revenue, net ​ $ 34,742 ​ $ 23,386 ​ $ 108 Collaboration revenues ​ ​ 926 ​ ​ 3,830 ​ ​ 2,756 Research premium and grant revenue ​ ​ 1,267 ​ ​ 1,679 ​ ​ 2,163 Total revenues ​ $ 36,935 ​ $ 28,895 ​ $ 5,027 ​ ​ Collaboration revenues for the year ended December 31, 2022 were $0.9 million related to the restructured China Region License Agreement (see Note 14), a portion of which is recognized over the estimated period the manufacturing collaboration and regulatory support will be provided to Sumitomo Pharmaceuticals (Suzhou). Collaboration revenues for the year ended December 31, 2021 include $2.6 million related to the restructured China Region License Agreement, a portion of which is recognized over the estimated period the manufacturing collaboration and regulatory support will be provided to Sumitomo Pharmaceuticals (Suzhou), as well as $1.2 million of the Company’s share of revenues associated with the SIVEXTRO distribution agreement with Merck through April 11, 2021 (see Note 14). Collaboration revenues for the year ended December 31, 2020 includes a $0.5 million regulatory milestone payment from Sunovion Pharmaceuticals Canada Inc., or Sunovion, $1.8 million for the Company´s share of revenues associated with the SIVEXTRO distribution agreement with Merck as well as collaboration revenues associated with the restructuring of the China Region License Agreement. The Company sells its products to pharmaceutical wholesalers/distributors (i.e., the Company’s customers). The Company’s wholesalers/distributors in turn sell the Company’s products directly to clinics, hospitals, and private practices. Revenue from the Company’s product sales is recognized as physical delivery of product occurs (when the Company’s customer obtains control of the product), in return for agreed-upon consideration. SIVEXTRO product revenues, net of gross-to-net, or GTN, accruals and adjustments for returns were $34.5 million for the year ended December 31, 2022 and $23.8 million for the year ended December 31, 2021. For the years ended December 31, 2022, 2021 and 2020 XENLETA product revenues, net of GTN accruals and adjustments for returns, were $0.2 million, $(0.4) million and $0.1 million, respectively, including revenues from the Company´s Named Patient Program, or NPP, with WE Pharma Ltd., or WEP Clinical, of $8,000 and $17,000 for the years ended December 31, 2022 and December 31, 2021. The Company´s gross-to-net, or GTN, estimates are based upon information received from external sources (such as written or oral information obtained from the Company´s customers with respect to their period-end inventory levels and sales to end-users during the period), in combination with management’s informed judgments. Due to the inherent uncertainty of these estimates, the actual amount incurred may be materially above or below the amount initially estimated when product revenues are originally recorded, then requiring prospective adjustments to the Company’s reported product revenues, net. For the year ended December 31, 2022, the Company recorded a $0.3 million returns reserve adjustment for shelf life expiration of certain XENLETA products. For the year ended December 31, 2021, the Company recorded a returns reserve adjustment of $1.3 million for slow-moving inventory, representing 50% of XENLETA IV inventory held at its specialty distributors, as well as an adjustment for returns from a single mail order specialty pharmacy.

Share Based Payments

Share Based Payments	12 Months Ended
	Dec. 31, 2022
Share Based Payments
Share Based Payments	10. Share Based Payments Stock Plan Activity On April 2, 2015, the Company’s shareholders, management board and supervisory board adopted the Stock Option Plan 2015, or the SOP 2015, as amended. Each vested option grants the beneficiary the right to acquire one share in the Company. The vesting period for the options is four years following the grant date. On the last day of the last calendar month of the first year of the vesting period, 25% of the options attributable to each beneficiary are automatically vested. During the second, third and fourth years of the vesting period, the remaining 75% of the options vest on a monthly pro rata basis (i.e. 2.083% per month). Options granted under the SOP 2015 have a term of no more than ten years from the beneficiary’s date of participation. With the approval of the 2017 Share Incentive Plan, there were no further shares available for issuance under the SOP 2015. However, all outstanding awards under SOP 2015 will remain in effect and continue to be governed by the terms of the SOP 2015. On July 26, 2017, the Company’s board of directors adopted the 2017 Share Incentive Plan, or the 2017 Plan, and the shareholders approved the 2017 Plan at the Company’s Extraordinary General Meeting of Shareholders on September 15, 2017. The 2017 Plan permitted the award of share options (both incentive and nonstatutory options), share appreciation rights, or SARs, restricted shares, restricted share units, or RSUs, and other share-based awards to the Company’s employees, officers, directors, consultants and advisers. The 2017 Plan is administered by the Company’s board of directors. Under the 2017 Plan, the Company granted RSUs which vest over a period of four years with 25% vesting upon the first anniversary of the grant date and on a monthly pro rata basis thereafter over the remaining three years. During 2018, the Company granted RSUs to certain employees where vesting of the RSUs was subject to FDA approval of an NDA for XENLETA. Fifty fifty approval that was received in August 2019, the Company started recognizing compensation expense, as there was no compensation expense recognized on these awards prior to the FDA approval as it was determined that approval was not probable since it was outside of the Company’s control. Also during 2018, the Company granted RSUs to certain employees that have vested in three six-month increments beginning in May 2019 and ending in May 2020. Lastly, the Company granted RSUs in 2018 to certain employees where vesting of the RSUs is subject to FDA approval of an NDA for CONTEPO. Fifty fifty ​ On March 12, 2019, the Company’s board of directors adopted the 2019 Inducement Share Incentive Plan, or the 2019 Inducement Plan and, subject to the adjustment provisions of the 2019 Inducement Plan, reserved 8,000 ordinary shares for issuance pursuant to equity awards granted under the 2019 Inducement Plan. In accordance with Nasdaq Listing Rule 5635(c)(4), awards under the 2019 Inducement Plan may only be made to individuals who were not previously employees or non-employee directors of the Company (or following such individuals’ bona fide period of non-employment with the Company), as an inducement material to the individuals’ entry into employment with the Company. On April 28, 2020, the board of directors resolved not to make any further awards under the 2019 Inducement Plan. In July 2018, the Company granted a non-statutory option to purchase 3,400 of its ordinary shares and 600 performance-based RSUs to the Company’s then newly appointed Chief Executive Officer, or the former CEO. These equity awards were granted outside of the 2017 Plan and the 2019 Inducement Plan, were approved by the Company’s compensation committee and board of directors and were made as an inducement material to the former CEO entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price per share for the share option is $882.50 per share, and the option award has a ten-year term and vests over a four-year period, with 25% of the shares underlying the award vesting on the first anniversary of the grant date and the remaining 75% of the shares underlying the option award to vest monthly over the subsequent 36-month period. The performance-based RSUs are subject to vesting as follows: 50% will vest upon certification by the board of directors of the receipt of approval by the FDA of an NDA for each of lefamulin and CONTEPO for any indication, and 50% will vest on the first anniversary of such certification by the board of directors, provided, in each case, the former CEO is performing services to the Company on the applicable vesting dates. If the FDA does not approve an NDA for both lefamulin and CONTEPO by January 31, 2020, the performance-based RSUs will terminate in full. Since CONTEPO was not approved by this date the award was forfeited. The Company also issues non-statutory options to new employees upon the commencement of their employment. On March 4, 2020, the Company´s board of directors adopted the 2020 Share Incentive Plan, or the 2020 Plan, which was approved by the Company´s shareholders at the 2020 Annual General Meeting of Shareholders in July 2020, or 2020 AGM. As of the date of the 2020 AGM, the total number of ordinary shares reserved for issuance under the 2020 Plan was for the sum of 37,200 ordinary shares, plus the number of the Company´s ordinary shares that remained available for grant under the 2017 Plan as of immediately prior to the AGM and the number of ordinary shares subject to awards granted under the 2017 Plan and the Company´s Amended and Restated Stock Option Plan 2015, that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right. The 2020 Plan provides for the grant of incentive share options, non-statutory share options, share appreciation rights, restricted share awards, restricted share units, other share-based and cash-based awards and performance awards. Under the 2020 Plan the Company granted RSUs to certain employees that vest in three six-month increments beginning in January 2021 and ending in January 2022. The Company also granted RSUs to certain employees, where vesting of the RSUs was subject to individual performance goals. During the year ended December 31, 2021, the Company granted RSUs to certain employees that vest in annual increments beginning January 2022 and ending in January 2025. Additionally, the Company granted 280 RSUs to its former Chief Medical Officer and to its former Chief Financial Officer, which vest as to 50% of the shares underlying the RSUs each year over the term of their respective consulting agreements. At December 31, 2022, 12,788 ordinary shares were available for future issuance under the 2020 Plan. On December 9, 2020, the Company´s board of directors adopted without stockholder approval the 2021 Inducement Share Incentive Plan, or the 2021 Inducement Plan and, subject to the adjustment provisions of the 2021 Inducement Plan, reserved 8,000 ordinary shares for issuance pursuant to equity awards granted under the 2021 Inducement Plan. In accordance with Nasdaq Listing Rule 5635(c)(4), awards under the 2021 Inducement Plan may only be made to individuals who were not previously employees or non-employee directors of the Company (or following such individuals’ bona fide period of non-employment with the company), as an inducement material to the individuals’ entry into employment with the Company. In September 2021, the Company’s board of directors adopted an amendment to the 2021 Inducement Plan that increased the amount of shares reserved for issuance under the plan from 8,000 shares to 20,000 shares. Options and SARs granted will be exercisable at such times and subject to such terms and conditions as the board may specify in the applicable option agreement; provided, however, that no option or SAR will be granted with a term in excess of ten years. The board will also determine the terms and conditions of restricted shares and RSUs, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any. ​ Stock Options The following table summarizes information regarding the Company´s stock option awards: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Weighted ​ Average ​ ​ ​ ​ ​ ​ ​ average ​ Remaining ​ Aggregate ​ ​ ​ ​ exercise ​ Contractual ​ intrinsic ​ ​ ​ ​ price in ​ Term ​ value ​ ​ Options ​ $ per share ​ (in years) ​ (in thousands) Outstanding as of January 1, 2022 ​ 53,885 $ 510.34 ​ 8.0 ​ ​ — Granted ​ 24,160 ​ 11.25 ​ ​ ​ ​ — Exercised ​ — ​ — ​ ​ ​ ​ — Cancelled and forfeited ​ (2,172) ​ 323.43 ​ ​ ​ ​ — Outstanding as of December 31, 2022 ​ 75,873 $ 351.24 ​ 7.7 ​ $ — Vested and exercisable as of December 31, 2022 ​ 38,490 $ 653.81 ​ 6.6 ​ $ — ​ The Company has 75,873 option grants outstanding at December 31, 2022 with exercise prices ranging from $11.25 per share to $2,750.00 per share. As of December 31, 2022, there was $0.7 million of total unrecognized compensation expense related to unvested stock options, which will be recognized over the weighted-average remaining vesting period of 0.1 years. The weighted average fair value of the stock options granted during years ended December 31, 2022, 2021 and 2020 was $11.05, $20.53 and $149.84 per share, respectively, based on a Black Scholes option pricing model using the following assumptions: ​ ​ ​ ​ ​ ​ ​ ​ Input parameters 2022 ​ 2021 ​ 2020 Range of expected volatility 76.4% - 76.9% ​ 75.3% ‑ 77.3% ​ 63.7% ‑ 74.4% Expected term of options (in years) 6.1 ​ 5.5 - 6.1 ​ 5.5 - 6.1 Range of risk-free interest rate 1.7% - 1.8% ​ 0.8% ‑ 1.3% ​ 0.8% ‑ 1.5% Dividend yield — ​ — ​ – ​ The expected price volatility is based on historical trading volatility of our ordinary shares under consideration of the remaining life of the options. The risk-free interest rate is based on the average of five ​ Restricted Stock Units (“RSUs”) The following table summarizes information regarding the Company’s restricted share unit awards: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ average grant date fair ​ RSUs ​ ​ value in $ per share Outstanding as of January 1, 2022 31,538 ​ $ 74.10 Granted 19,566 ​ ​ 11.04 Vested and issued (9,512) ​ ​ 85.25 Forfeited (2,957) ​ ​ 41.72 Outstanding as of December 31, 2022 38,635 ​ $ 41.89 ​ As of December 31, 2022, there was unrecognized compensation costs of $0.5 million associated with RSUs which are expected to be recognized over the awards average remaining vesting period of 0.1 years. The intrinsic value of RSU’s that vested during the years ended December 31, 2022, 2021 and 2020 was $0.1 million, $0.2 million and $0.4 million, respectively. Stock-based Compensation The following table presents stock-based compensation expense included in the Company’s consolidated statements of operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, (in thousands) 2022 2021 2020 Research and development expense $ 123 ​ $ 565 ​ $ 1,280 Selling, general and administrative expense ​ 1,844 ​ ​ 2,726 ​ ​ 3,939 Total stock-based compensation expense $ 1,967 ​ $ 3,291 ​ $ 5,219 ​ Employee Stock Purchase Plan The Company’s board of directors adopted, and in August 2018 Company’s stockholders approved, the 2018 employee stock purchase plan, or the 2018 ESPP. The maximum aggregate number of shares of ordinary shares that may be purchased under the 2018 ESPP is 2,000 shares, or the ESPP Share Pool, subject to adjustment as provided for in the 2018 ESPP. The 2018 ESPP allowed eligible employees to purchase shares at a 15% discount to the lower of the closing share price at the beginning and end of the six-month offering periods commencing November 1 and ending April 30 and commencing May 1 and ending October 31 of each year. The Company suspended the 2018 ESPP in April 2020.

Post-employment Benefit Obligat

Post-employment Benefit Obligations	12 Months Ended
	Dec. 31, 2022
Post-employment Benefit Obligations
Post-employment Benefit Obligations	11. Post-employment Benefit Obligations As required under Austrian labor law, the Company makes contributions to a state plan classified as defined contribution plan (Mitarbeitervorsorgekasse) for its employees in Austria. Monthly contributions to the plan are 1.53% of salary with respect to each employee and are recognized as expense in the period incurred. For the years ended December 31, 2022, 2021 and 2020, contributions costs were $49,000, $56,000 and $57,000 respectively. For employees of Nabriva Therapeutics US, Inc., the Company makes contributions to a defined contribution plan as defined in subsection 401(k) of the Internal Revenue Code. The Company matches 100% of the first 3% of the employee’s voluntary contribution to the plan and 50% of the next 2% contributed by the employee. Contributions are recognized as expense in the period incurred. In the years ended December 31, 2022, 2021 and 2020, contributions were $383,000, $360,000 and $396,000 respectively. The Company terminated its matching policy in January 2023.

Income Tax Expense

Income Tax Expense	12 Months Ended
	Dec. 31, 2022
Income Tax Expense
Income Tax Expense	12. Income Tax Expense Income (loss) before income taxes attributable to domestic and international operations, consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 (in thousands) 2022 2021 2020 Domestic ​ $ (54,235) ​ $ (40,540) ​ $ (71,344) Foreign ​ (1,382) ​ (8,420) ​ 1,999 Loss before income taxes ​ $ (55,617) ​ $ (48,960) ​ $ (69,345) ​ Income tax expense consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 (in thousands) 2022 2021 2020 Current tax ​ ​ ​ ​ ​ ​ ​ ​ ​ Domestic ​ $ (1) ​ $ — ​ $ — Foreign ​ (1,567) ​ (490) ​ (139) Deferred tax ​ ​ ​ ​ ​ ​ ​ ​ ​ Domestic ​ ​ ​ — ​ — Foreign ​ ​ ​ — ​ — Total income tax expense ​ $ (1,568) ​ $ (490) ​ $ (139) ​ The reconciliation to our effective tax rate from the Irish statutory income tax rate of 12.5% for the years ended December 31, 2022, 2021 and 2020 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 ​ (% of pre-tax income) 2022 2021 2020 ​ Statutory income tax rate 12.5 % 12.5 % 12.5 % Income not subject to tax 0.3 ​ 0.4 ​ 0.2 ​ Tax credits 0.6 ​ 0.0 ​ 0.6 ​ Foreign operations ​ (8.1) ​ (7.3) ​ 3.0 ​ Other 0.3 ​ (1.7) ​ 2.3 ​ Valuation allowance (8.4) ​ (4.9) ​ (18.8) ​ Effective income tax rate (2.8) % (1.0) % (0.2) % ​ The following table summarizes the components of deferred income tax balances: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands) 2022 2021 Deferred tax assets: ​ ​ ​ ​ Net operating loss carryforwards ​ $ 116,080 ​ $ 111,220 Tax loss on liquidation of subsidiary ​ ​ 1,184 ​ ​ 2,501 Equity compensation ​ 4,258 ​ 4,067 Non-deductible reserves ​ 2,118 ​ 905 Total deferred tax assets ​ ​ 123,640 ​ ​ 118,693 Valuation allowance ​ (123,277) ​ (118,583) Net deferred tax assets ​ ​ 363 ​ ​ 110 Deferred tax liabilities: ​ ​ ​ ​ ​ ​ Financial liabilities ​ ​ 363 ​ 100 Property and equipment ​ — ​ 10 Total deferred tax liability ​ ​ 363 ​ ​ 110 Deferred tax, net ​ $ — ​ $ — ​ The table below summarizes changes in the deferred tax valuation allowance: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands) 2022 2021 2020 Balance at beginning of year $ (118,583) $ (116,200) $ (103,185) Tax benefit ​ (4,694) ​ (2,383) ​ (13,015) Balance at end of year ​ $ (123,277) $ (118,583) $ (116,200) ​ The following table summarizes carryforwards of net operating losses as of December 31, 2022. ​ ​ ​ ​ ​ ​ ​ (in thousands) Amount Expiration Ireland ​ $ 350,597 Indefinite Austria ​ $ 232,679 Indefinite United States ​ $ 10,403 ​ Indefinite United States ​ $ 35,246 2033 ​ Due to uncertainty regarding the ability to realize the benefit of deferred tax assets primarily relating to net operating loss carryforwards and the fact that the Company is in a three year pretax cumulative loss position, a full valuation allowance has been established. The Company’s U.S. subsidiary has net operating loss and tax credit carryforwards that may be subject to annual limitations due to ownership changes as defined by Sections 382 and 383 of the Internal Revenue Code. These limitations could restrict the amount of tax attributes that can be utilized annually to offset future U.S. taxable income or tax liabilities. On the basis of this evaluation, as of December 31, 2022, 2021 and 2020, the Company has recorded a valuation allowance of $123.3 million, $118.6 million and $116.2 million, respectively, to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as our projections for growth. At December 31, 2022, the Company had no uncertain tax positions and did not expect any material increase or decrease in income tax expense related to examinations or changes in uncertain tax positions. The Company files income tax returns in Ireland. In addition, the Company’s foreign subsidiaries file separate income tax returns in Austria and the United States and state jurisdictions in which they are located. Tax years 2018 and forward remain open for examination for Ireland tax purposes and 2017 and forward remain open for examination for Austrian tax purposes and years 2019 and forward remain open for examination for United States tax purposes. The Company’s policy is to record interest and penalties related to tax matters in income tax expense.

Earnings (Loss) per Share

Earnings (Loss) per Share	12 Months Ended
	Dec. 31, 2022
Earnings (Loss) per Share
Earnings (Loss) per Share	13. Earnings (Loss) per Share Basic and Diluted Loss per Share Basic and diluted loss per share is calculated by dividing the net loss attributable to stockholders by the weighted average number of shares outstanding during the year. Diluted net loss per share is the same as basic net loss per share during the periods presented as the effects of the Company’s common stock equivalents are antidilutive and thus not included in the calculation. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands, except share and per share data) 2022 2021 2020 Net loss for the period ​ $ (57,185) ​ $ (49,450) ​ $ (69,484) Weighted average number of shares outstanding ​ 2,681,968 ​ 1,733,978 ​ 513,804 Basic and diluted loss per share ​ $ (21.32) ​ $ (28.52) ​ $ (135.23) ​ The following ordinary share equivalents were excluded from the calculations of diluted loss per share as their effect would be anti-dilutive: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 ​ 2022 2021 2020 Stock option awards ​ 75,873 ​ 53,939 ​ 42,113 Restricted share units ​ 38,635 ​ 31,589 ​ 9,575 Warrants ​ 262,384 ​ 424,773 ​ 217,553 ​

Significant Arrangements and Li

Significant Arrangements and License Agreements	12 Months Ended
	Dec. 31, 2022
Significant Arrangements and License Agreements
Significant Arrangements and License Agreements	14. Significant Arrangements and License Agreements Er-Kim License Agreement ​ ​ Sales Promotion and Distribution Agreement with Merck & Co. On July 15, 2020, the Company entered into a the Distribution Agreement, with MSD and Supplier, each a subsidiary of Merck. Under the Distribution Agreement and subject to the satisfaction of certain conditions, MSD appointed the Company as its sole and exclusive distributor of certain products containing tedizolid phosphate as the active ingredient previously marketed and sold by Supplier and MSD under the trademark SIVEXTRO® for injection, intravenous use and oral use, or the Products, in the United States and its territories, or the SIVEXTRO Territory. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible Gram-positive microorganisms. On April 12, 2021, in accordance with the terms of the Distribution Agreement, the Company began exclusive distribution of SIVEXTRO under its own National Drug Code, or NDC, and the Company recognizes 100% of net product sales of SIVEXTRO in its results of operations. Subject to applicable law, the Company is entitled to determine the final selling prices of the Products charged by it to its customers at its sole discretion, subject to an overall annual limit on price increases, and will be solely responsible for sales contracting and all market access activities, including bidding, hospital listing and reimbursement. The Company is responsible for all costs related to the promotion, sale and distribution of the Products by it, as well as all costs required to meet its staffing obligations under the Distribution Agreement. Prior to the execution of the Letter Agreement, the Company was obligated to use commercially reasonable efforts to promote and distribute the Products and to maximize the sales of the Products throughout the SIVEXTRO Territory and utilized a combination of its employees and assistance from Amplity Health, a contract sales organization, to comply with this obligation. On January 31, 2023, the Company entered into the Letter Agreement which, among other things, converted its exclusive license to promote, distribute and commercialize SIVEXTRO to a non-exclusive license and provided for the termination of the Distribution Agreement, effective June 30, 2023. ​ China Region License Agreement In March 2018, the Company entered into the China Region License Agreement, with Sinovant Sciences, Ltd., or Sinovant, an affiliate of Roivant Sciences, Ltd., to develop and commercialize lefamulin in the greater China region. As part of the China Region License Agreement, Nabriva Therapeutics Ireland DAC and Nabriva Therapeutics GmbH, the Company’s wholly owned subsidiaries, granted Sinovant an exclusive license to develop and commercialize, and a non-exclusive license to manufacture, certain products containing lefamulin, or the China Region Licensed Products, in the People’s Republic of China, Hong Kong, Macau, and Taiwan, together the Extended China Territory. In May 2021, the Company entered into an assignment, assumption and novation agreement, or the Assignment Agreement, pursuant to which the Company consented to the assignment by Sinovant, an affiliate of Roivant Sciences, Ltd., of the China Region License Agreement to develop and commercialize lefamulin in the greater China region to Sumitomo Pharmaceuticals (Suzhou), a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo”). Pursuant to the Assignment Agreement, the Company agreed to release Sinovant and its affiliates from their obligations under the China Region License Agreement and consented to Sumitomo Pharmaceuticals (Suzhou)’s assumption of such obligations. In addition, Sumitomo Dainippon Pharma Co., Ltd., or Sumitomo, has agreed to guarantee all of the obligations of Sumitomo Pharmaceuticals (Suzhou) under the China Region License Agreement. Under the China Region License Agreement, Sumitomo Pharmaceuticals (Suzhou) and the Company’s subsidiaries have established a joint development committee, or the JDC, to review and oversee development and commercialization plans in the Extended China Territory. The China Region License Agreement includes milestone events consisting of a non-refundable $5.0 million upfront payment, an additional $91.5 million in milestone payments upon the achievement of certain regulatory and commercial milestone events related to lefamulin for CABP, plus an additional $4.0 million in milestone payments if any China Region Licensed Product receives a second or any subsequent regulatory approval in the People’s Republic of China. The Company has received the $5.0 million upfront payment, a $1.5 million payment for the submission of a clinical trial application, or CTA, by Sinovant to the Chinese Food and Drug Administration, which was received in the first quarter of 2019 and a $5.0 million milestone payment in the third quarter of 2019 in connection with the FDA approval for lefamulin. The Company will also be eligible to receive low double-digit royalties on sales, if any, of China Region Licensed Products in the Extended China Territory. In December 2020, the Company announced the restructuring of its China Region License Agreement. The restructured agreement provided for additional manufacturing collaboration and regulatory support to be provided to the contract counterparty by the Company that is expected to help expedite the delivery of XENLETA to patients in greater China. The restructured agreement also accelerated $3.0 million of the $5.0 million milestone payment to the Company that was previously payable upon regulatory approval of XENLETA in China, including a non-refundable upfront payment of $1.0 million which was received in the fourth quarter of 2020 and a $1.0 million milestone achieved during the first quarter of 2021. During 2021, management determined that the remaining $1.0 million milestone payment was probable of achievement and therefore the Company is recognizing the $3.0 million of accelerated payments under the restructured agreement as collaboration revenue in the consolidated statements of operations over the estimated period the manufacturing collaboration and regulatory support will be provided to the contract counterparty, which was $0.6 million and $2.4 million for the years ended December 31, 2022 and 2021, respectively, based on the proportional performance of the underlying performance obligation. The remaining milestones of $86.0 million are tied to additional regulatory approvals and annual sales targets. The future regulatory and commercial milestone payments under the China Region License Agreement will be recorded during the period the milestones become probable of achievement. Except for the manufacturing collaboration and regulatory support discussed above, Sumitomo Pharmaceuticals (Suzhou) will be solely responsible for all costs related to developing, obtaining regulatory approval of and commercializing China Region Licensed Products in the Extended China Territory and is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize China Region Licensed Products in the Extended China Territory. The Company is obligated to use commercially reasonable efforts to supply, pursuant to supply agreements to be negotiated by the parties, to Sumitomo Pharmaceuticals (Suzhou) a sufficient supply of lefamulin for Sumitomo Pharmaceuticals (Suzhou) to manufacture finished drug products for development and commercialization of the China Region Licensed Products in the Extended China Territory. Unless earlier terminated, the China Region License Agreement will expire upon the expiration of the last royalty term for the last China Region Licensed Product in the Extended China Territory, which the Company expects will occur in 2033. Following the expiration of the last royalty term, the license granted to Sumitomo Pharmaceuticals (Suzhou) will become non-exclusive, fully-paid, royalty-free and irrevocable. The China Region License Agreement may be terminated in its entirety by Sumitomo Pharmaceuticals (Suzhou) upon 180 days’ prior written notice at any time. Either party may, subject to specified cure periods, terminate the China Region License Agreement in the event of the other party’s uncured material breach. Either party may also terminate the China Region License Agreement under specified circumstances relating to the other party’s insolvency. The Company has the right to terminate the China Region License Agreement immediately if Sumitomo Pharmaceuticals (Suzhou) does not reach certain development milestones by certain specified dates (subject to specified cure periods). The China Region License Agreement contemplates that the Company will enter into ancillary agreements with Sumitomo Pharmaceuticals (Suzhou), including clinical and commercial supply agreements and a pharmacovigilance agreement. Sunovion License Agreement In March 2019, the Company entered into the Sunovion License Agreement with Sunovion. As part of the Sunovion License Agreement, Nabriva Therapeutics Ireland DAC, the Company’s wholly owned subsidiary, granted Sunovion an exclusive license under certain patent rights, trademark rights and know-how to commercialize certain products containing XENLETA in the forms clinically developed by the Company or any of its affiliates, or the Sunovion Licensed Products, in Canada in all uses in humans in CABP and in any other indication for which the Sunovion Licensed Products have received regulatory approval in Canada. Under the Sunovion License Agreement, Sunovion and DAC established a joint development committee, or the Sunovion JDC, to review and oversee regulatory approval and commercialization plans in Canada. Sunovion will be solely responsible for all costs related to obtaining regulatory approval of and commercializing Sunovion Licensed Products in the Canada and is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize Licensed Product in Canada. On November 7, 2019, the Company, through Sunovion, submitted a New Drug Submission, or NDS. Health Canada determined there was a screening deficiency in December 2019 and a response from the Company/Sunovion was provided on December 18, 2019 and acknowledged by Health Canada on January 13, 2020. The NDS approval occurred on July 10, 2020. The Company identified two performance obligations at inception: (1) the delivery of the exclusive license to Sunovion, which the Company has determined is a distinct license of functional intellectual property that Sunovion has obtained control of; and, (2) the participation in the Sunovion JDC. The $1.0 million non-refundable upfront payment was allocated entirely to the delivery of the license as the Sunovion JDC deliverable was deemed to be de minimis. With the NDS approval that occurred on July 10, 2020, the Company received a regulatory milestone payment of $0.5 million. Any future regulatory and commercial milestone payments under the Sunovion License Agreement will be recorded during the period the milestones become probable of achievement. Named Patient Program Agreement with WE Pharma Ltd. On June 30, 2020 the Company announced that WEP Clinical, a specialist pharmaceutical services company, had signed an exclusive agreement with the Company to supply XENLETA on a named patient or expanded access basis in certain countries outside of the US, China and Canada. The NPP is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet available and have an unmet medical need. On January 9, 2023, the Company provided WEP Clinical with notice of its intent to terminate the agreement in connection with the orderly wind down of of its operations. ​

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies
Commitments and Contingencies	15. Commitments and Contingencies Future minimum contractual obligations and commitments at December 31, 2022 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ending December 31, (in thousands) Total 2023 2024 2025 2026 2027 Thereafter Operating lease obligations ​ $ 892 ​ ​ 892 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ $ — XENLETA API purchase ​ ​ 39,145 ​ ​ 3,317 ​ ​ 3,317 ​ ​ 4,704 ​ ​ 4,704 ​ ​ 4,704 ​ ​ 18,399 Other contractual commitments ​ 5,965 ​ 3,729 ​ 1,360 ​ 876 ​ — ​ — ​ — Total contractual commitments and contingencies ​ $ 46,002 ​ $ 7,938 ​ $ 4,677 ​ $ 5,580 ​ $ 4,704 ​ $ 4,704 ​ $ 18,399 ​ The Company has contractual commitments related primarily to contracts entered into with contract manufacturing organizations and contract research organizations in connection with the commercial manufacturing of XENLETA. The amounts included in the table above are based on the existing contractual terms included within the agreements. Also, some of these contracts are subject to early termination clauses exercisable at the discretion of the Company. Due to the Company’s intention to wind down operations and pursue the asset sales of XENLETA and CONTEPO, some amounts above have been accrued for at December 31, 2022 to comply with ASC 330-10-35-17, Inventory Purchase Commitments regarding potential losses that a reporting entity may sustain as a result of firm purchase commitments ​ XENLETA API Supply On August 4, 2021, our wholly-owned subsidiary, Nabriva Therapeutics Ireland DAC, entered into an amendment, or the First Amendment, to its API Supply Agreement, or the Hovione Supply Agreement, with Hovione Limited, or Hovione, which provides for the long-term commercial supply of the active pharmaceutical ingredients, or API, for XENLETA. Under the First Amendment, Hovione agreed to cancel the Company’s May 2021 purchase order for XENLETA API, which represented the Company’s minimum purchase requirement under the Hovione Supply Agreement. In addition, pursuant to the First Amendment, Hovione agreed to reduce the Company’s annual minimum purchase requirements for XENLETA API to no minimum purchase requirement in 2021, by 50% from 2022 to 2024 and by 25% in 2025, in consideration for cash payments totaling €3.2 million and the right to a low single-digit royalty on total net sales of XENLETA in the United States for a period commencing on August 4, 2021 and ending on November 22, 2030, or the Royalty Term, which royalty payments shall be no greater than an aggregate of €10.0 million. If the aggregate amount of royalties payments received by Hovione under the First Amendment is less than an aggregate of €4.0 million, we are obligated to pay Hovione the difference in a lump sum payment at the end of the Royalty Term. In addition, pursuant to the First Amendment, Hovione agreed to extend the duration of the Hovione Supply Agreement from November 22, 2025 to November 22, 2030 with annual minimum purchase requirements for 2026 to 2030 at the newly agreed annual minimum purchase amount for 2025. Pursuant to the First Amendment, upon the occurrence of certain events of insolvency for us, any unpaid minimum annual commitment amounts and royalty amounts under the agreement will become immediately due and payable . ​ On November 11, 2022, the Company’s wholly-owned subsidiary, Nabriva Therapeutics Ireland DAC, entered into an amendment, or the Third Amendment, to the Hovione Supply Agreement. Under the Third Amendment, Hovione agreed to reduce the Company’s annual minimum purchase requirements for XENLETA API for certain geographies. In consideration for the reduced minimum purchase requirements, the Company granted Hovione the right to a low single-digit royalty on total net sales of XENLETA by the Company’s licensees outside of the United States to the extent that the commercial product of XENLETA sold by such licensees is manufactured with API obtained from a third party (or any finished commercial product containing API obtained from a third party) other than Hovione during the terms of the agreement. Zavante Ob l igations In connection with the acquisition of Zavante in July 2018, the Company is obligated to pay up to $97.5 million in contingent consideration to the former Zavante shareholders, of which $25.0 million would become payable upon the first approval of a NDA from the FDA for CONTEPO for any indication, or the Approval Milestone Payment, and an aggregate of up to $72.5 million would become payable upon the achievement of specified sales milestones, or the Net Sales Milestone Payments. The Company’s shareholders have approved the issuance of the Company’s ordinary shares in settlement of potential milestone payment obligations that may become payable in the future to former Zavante stockholders, including the Approval Milestone Payment which will be settled in Company ordinary shares. The Company also has the right to settle the Net Sales Milestone Payments in Company ordinary shares, except as otherwise provided in the Agreement and Plan of Merger, dated July 23, 2018, by and among Nabriva Therapeutics plc and certain of its subsidiaries and Zavante Therapeutics, Inc. and Cam Gallagher, solely in his capacity as representative of the former Zavante stockholders, or the Merger Agreement. The Company is obligated to pay $3.0 million in cash upon marketing approval by the FDA with respect to any oral, intravenous or other form of fosfomycin, or the Zavante Products, and milestone payments of up to $26.0 million that may be settled in ordinary shares in the aggregate upon the occurrence of various specified levels of net sales with respect to the Zavante Products. In addition, Zavante is obligated to make annual royalty payments of a mid-single-digit percentage of net sales of Zavante Products, subject to adjustment based on net sales thresholds and with such percentage reduced to low single-digits if generic fosfomycin products account for half of the applicable market on a product-by-product and country-by-country basis. Zavante will also pay a mid-single-digit percentage of transaction revenue in connection with the consummation of the grant, sale, license or transfer of market exclusivity rights for a qualified infectious disease product (within the meaning of the 21st Century Cures Act) related to a Zavante Product. Litigation The Company has no contingent liabilities in respect of legal claims arising in the ordinary course of business.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events
Subsequent Events	16. Subsequent Events On January 5, 2023, the Company repaid $4.5 million to Hercules Capital, including principal, accrued and unpaid interest, fees and other expenses, under its loan agreement. Effective at the time of repayment, the Hercules loan agreement was terminated, and Hercules released all security interests held on the assets of the Company and its subsidiaries. ​ On January 6, 2023, the Company announced that the board of directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company’s operations, while the Company continues to work with Torreya Capital to advance discussions and facilitate the exploration of a range of strategic options. The priority remains focusing on the sale of its existing assets, including Lefamulin and IV Fosfomycin. The Company incurred approximately $6.0 million for severance and other employee termination-related costs, including severance costs for members of the Amplity Health sales force, in the first quarter of 2023. ​ On January 31, 2023, the Company agreed on a letter agreement with Merck to continue to distribute SIVEXTRO in the United States. The Company’s exclusive license to promote, distribute and commercialize SIVEXTRO was converted to a non-exclusive license, and the parties agreed to terminate the Distribution Agreement, effective June 30, 2023. The Company no longer intends to actively promote SIVEXTRO but expect to continue to make SIVEXTRO available to wholesale customers and record revenue from any such sales until June 30, 2023. After June 30, 2023, the Company will no longer have the right to promote, distribute or commercialize SIVEXTRO. ​ ​ ​ ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies
Basis of Preparation	Basis of Preparation The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or US GAAP, and SEC regulations for annual reporting. The consolidated financial statements include the accounts of Nabriva Therapeutics plc and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Reverse Stock Split	Reverse Stock Split On September 16, 2022, the Company filed an Amended and Restated Memorandum and Articles of Association of the Company with the Irish Companies Registration Office and effected, a one twenty five
Functional Currency Transactions and Balances	Functional Currency Transactions and Balances In preparing the consolidated financial statements, transactions in currencies other than the U.S. dollar are recognized at the exchange rates prevailing at the dates of the transactions. Foreign currency exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statements of operations.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. Cash as of December 31, 2022 solely consisted of deposits at banking institutions, which may exceed Federal Deposit Insurance Corporation insured limits.
Short-term Investments	Short-term Investments The Company has designated its investments in securities as available-for-sale securities and measures these securities at their respective fair values. Investments that mature in one year or less are classified as short-term available-for-sale securities. Investments that are not considered available for use in current operations are classified as long-term available-for-sale securities. Changes in the fair value of available-for-sale investments are recognized in other comprehensive income (loss).
Inventory	Inventory ​ Inventory is stated at the lower of cost or net realizable value. Inventory is valued on a first-in, first-out basis and consists primarily of material costs, third-party manufacturing costs, and related transportation costs along the Company's supply chain. The Company capitalizes inventory upon regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are recorded as research and development expense. Costs of drug product to be consumed in any current or future clinical trials will continue to be recognized as research and development expense and costs of sample inventory is recorded as selling, general and administrative expense. The Company reviews inventories for realization on a quarterly basis and records provisions for estimated excess, slow-moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value when necessary. ​ The components of our inventory at December 31, 2022 and 2021 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ As of ​ December 31, ​ ​ December 31, (in thousands) ​ 2022 ​ ​ 2021 XENLETA raw materials $ 916 ​ $ 1,528 XENLETA work in process 4,658 ​ 9,142 XENLETA finished goods ​ 640 ​ ​ 18 Total XENLETA ​ 6,214 ​ ​ 10,688 SIVEXTRO finished goods 3,462 ​ 3,821 Total inventory $ 9,676 ​ $ 14,509 ​
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property and equipment are as follows: 3 5 3
Intangible Assets and Other Long-lived Assets	Intangible Assets and Other Long-lived Assets Intangible assets, such as acquired computer software licenses, are capitalized on the basis of the costs incurred to acquire the software and bring it into use. These costs are amortized on a straight-line basis over their estimated useful lives ( 3 Long-lived assets are assessed for potential impairment when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. An impairment loss would be recognized when undiscounted cash flows expected to be generated by an asset, is less than its carrying amount. The impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value and recognized in these financial statements.
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating segment, which is the commercialization and development of novel anti-infective agents to treat serious and life-threatening infections.
Revenue Recognition	Revenue Recognition Revenue from Contracts with Customers Net Product Revenue In September 2019, the Company launched XENLETA and in April 2021 the Company began exclusive distribution of SIVEXTRO in the United States and certain of its territories. The Company sells its products principally to a limited number of specialty distributors and wholesalers. The Company recognizes revenue once it has transferred physical possession of the goods and the customer obtains legal title to the product. Payment terms between Nabriva and its customers are generally approximately 60 days from the invoice date. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of its product. The transaction price that the Company recognizes as revenue reflects the amount it expects to be entitled to in connection with the sale and transfer of control of product to its customers. At the time that the Company’s customers take control of the product, which is when the Company’s performance obligation under the sales contracts is complete, the Company records product revenues net of applicable reserves for various types of variable consideration. The types of variable consideration are as follows: ● fees-for-service; ● product returns; ● chargebacks and rebates; ● government rebates; ● commercial payer and other rebates; ● Group Purchasing Organizations, or GPO, administration fees; and ● voluntary patient assistance programs. In determining the amounts of certain allowances and accruals, the Company must make significant judgments and estimates. For example, in determining these amounts, the Company estimates prescription demand from retail pharmacies, specialty pharmacies, hospital demand, buying patterns by hospitals, hospital systems and/or group purchasing organizations and the levels of inventory held by distributors and customers. The Company also analyzes third party end usage product consumption patterns to gauge demand for its products. Making these determinations involves analyzing third party industry data to determine whether trends in historical channel distribution patterns will predict future product sales. The Company receives data periodically from its customers on inventory levels and historical channel sales mix, and the Company considers this data when determining the amount of the allowances and accruals for variable consideration. In assessing the amount of net revenue to record, the Company considers both the likelihood and the magnitude of the revenue reversal. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. The specific considerations the Company uses in estimating these amounts related to variable consideration associated with the Company’s products are as follows: Fees-for-service does not consider the fees separate from the distributors’ purchase of the product. The Company records its fee-for-service accruals based on distributors’ purchases and the applicable discount rate. Product returns history of SIVEXTRO and XENLETA returns, the Company estimated returns based on industry data for comparable products in the market. As the Company distributes its product and establishes historical sales over a longer period of time, the Company will be able to place more reliance on historical purchasing, demand and return patterns of its customers when evaluating its reserves for product returns. The Company’s XENLETA product has a forty-eight month shelf life and SIVEXTRO has a thirty-six month shelf life. The Company’s customers also have the right to return excess inventory on new products that do not yield forecasted sales. To the extent the Company’s customers determine that the quantities they purchased are in excess of their customers demand, product returns could increase in excess of what the Company has currently reserved which would result in a reduction to net revenues in future periods. ​ At the end of each reporting period for any of its products, the Company may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of product currently being shipped, price changes of competitive products and introductions of generic products. Chargebacks and rebates Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, p ublic h ealth s ervice institutions, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company’s wholesalers or specialty distributors. Contracted customers generally purchase the product at a discounted price. The Company provides a credit to its wholesaler or specialty distributor customers (i.e., chargeback), representing the difference between the customer’s acquisition list price and the discounted price. The calculation of the accrual for chargebacks and rebates is based on estimates of claims and their associated cost that the Company expects to receive associated with product sales that have been recognized as revenue but remain in the distribution channel as inventory at the end of each reporting period. Government rebates –The Company is subject to discount obligations primarily under state Medicaid and Medicare programs. The Company estimates its Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payer mix. These reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The calculation of the accrual for government rebates is based on estimates of claims and their associated cost that the Company expects to receive associated with product sales that have been recognized as revenue but remain in the distribution channel as inventory at the end of each reporting period. Commercial payer and other rebates cost that the Company expects to receive associated with product sales that have been recognized as revenue but remain in the distribution channel as inventory at the end of each reporting period. GPO administration fees – The Company contracts with GPOs and pays administration fees related to contacting and membership management services provided. In assessing if the consideration paid to the GPO should be recorded as a reduction in the transaction price, the Company determines whether the payment is for a distinct good or service or a combination of both. Since GPO fees are not specifically identifiable, the Company does not consider the fees separate from the purchase of the product. Additionally, the GPO services generally cannot be provided by a third party. Because of these factors, the consideration paid is considered a reduction of revenue. Patient assistance At the end of each reporting period, the Company will adjust its variable consideration estimates for product returns, chargebacks, and rebates when the Company believes actual experience may differ from current estimates. Cost of Revenues Cost of revenues for XENLETA primarily represents direct and indirect manufacturing costs, while cost of revenues for SIVEXTRO represent the actual purchase cost for the finished product from Merck. For the years ended December 31, 2022 and 2021, cost of revenues include a $5.2 million and $0.3 million non-cash charge for the net realizable value of inventory related to the potential asset sale of XENLETA ​
Research Premium and Grant Revenue	Research Premium and Grant Revenue Grant revenue comprises (a) the research premium from the Austrian government, (b) grants received from the Austrian Research Promotion Agency ( Österreichische Forschungsförderungsgesellschaft, or FFG The research premium the Company receives from the Austrian government is calculated at a specified percent of specified research and development cost base. The Company recognizes the research premium as long as it has incurred research and development expenses. All grants are non-refundable as long as the conditions of the grant are met. Nabriva is and has been in full compliance with the conditions of the grants and all related regulations.
Research and Development Expenses	Research and Development Expenses All research and development costs are expensed as incurred. Research and development costs included direct personnel and material costs, related overheads, depreciation of equipment used for research or development purposes; costs for clinical research; costs for the utilization of third parties’ patents for research and development purposes and other taxes related to research facilities.
Share-based Payments	Share-based Payments The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award in accordance with ASC 718, Compensation — Stock Compensation fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured.
Leases	Leases The Company follows ASC Topic 842, Leases The Company determines if an arrangement is a lease at inception. Operating lease right-of-use, or ROU, assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the remaining lease term. ROU assets are included in property and equipment, and operating lease liabilities are included in accrued expenses on the Company’s consolidated balance sheet. The Company has elected not to recognize ROU assets or lease liabilities for short-term leases. Since none of the Company’s lease agreements provide an implicit rate, the Company estimates an incremental borrowing rate over the lease term in determining the present value of lease payments. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as operating costs and property taxes are expensed as incurred.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. In recognizing the benefit of tax positions, the Company has taken or expects to take, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company’s policy is to record interest and penalties related to tax matters in income tax expense.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company has not adopted any new accounting pronouncements for the year ended December 31, 2022, nor are there any recently issued accounting pronouncements that are expected to have a material impact on the Company´s consolidated financial statements in future periods.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies
Schedule of inventory	​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ As of ​ December 31, ​ ​ December 31, (in thousands) ​ 2022 ​ ​ 2021 XENLETA raw materials $ 916 ​ $ 1,528 XENLETA work in process 4,658 ​ 9,142 XENLETA finished goods ​ 640 ​ ​ 18 Total XENLETA ​ 6,214 ​ ​ 10,688 SIVEXTRO finished goods 3,462 ​ 3,821 Total inventory $ 9,676 ​ $ 14,509 ​

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Measurement
Schedule of the financial instruments measured at fair value and classified by level according to the fair value measurement hierarchy	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Total December 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalent: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market fund ​ $ — ​ $ — ​ $ — $ — Total assets ​ $ — ​ $ — ​ $ — $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Total December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalent: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market fund ​ $ 8,050 ​ $ — ​ $ — $ 8,050 Short-term investments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Term deposits ​ 16 ​ — ​ — ​ 16 Total assets ​ $ 8,066 ​ $ — ​ $ — $ 8,066 ​

Accounts Receivable, net and _2

Accounts Receivable, net and Other Receivables (Tables)	12 Months Ended
	Dec. 31, 2022
Accounts Receivable, net and Other Receivables
Schedule of other current receivables	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31 (in thousands) 2022 2021 Receivables from customers, net ​ $ 3,208 ​ $ 8,778 Receivables from collaborative arrangements ​ ​ 274 ​ ​ 2,193 Research premium ​ ​ 2,472 ​ ​ 1,237 Other receivables ​ 788 ​ 543 Total accounts receivable, net and other receivables ​ $ 6,742 ​ $ 12,751 ​
Schedule of balances and activity of product revenue allowances and reserves	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ ​ 2022 ​ 2021 Receivables from customers ​ $ 5,168 ​ $ 10,149 Less: fee for service ​ (832) ​ (924) Less: chargeback reserve ​ (902) ​ (249) Less: cash discount ​ (226) ​ (198) Receivables from customers, net ​ $ 3,208 ​ $ 8,778

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property and Equipment
Schedule of property and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31 (in thousands) 2022 2021 IT equipment ​ $ 1,095 ​ $ 1,083 Laboratory equipment ​ 3,604 ​ 3,404 Other equipment ​ 100 ​ 101 ​ ​ ​ 4,799 ​ ​ 4,588 Less: Accumulated depreciation ​ ​ (4,519) ​ ​ (4,355) Property and equipment, net ​ $ 280 ​ $ 233

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Accrued Expenses and Other Current Liabilities
Schedule of accrued expenses and other liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31 (in thousands) ​ 2022 ​ ​ 2021 Research and development related costs ​ $ 707 ​ $ 789 Payroll and related costs ​ 1,737 ​ 5,085 Accounting, tax and audit services ​ 552 ​ 736 Manufacturing and inventory ​ ​ 8,113 ​ ​ 592 Product returns ​ ​ 784 ​ ​ 2,282 Government rebates ​ ​ 2,028 ​ ​ 1,751 Other accrued gross to net ​ ​ 2,129 ​ ​ 1,090 Other ​ 1,291 ​ 1,504 Total accrued expenses and other current liabilities ​ $ 17,341 ​ $ 13,829 ​
Schedule of reserve for product returns	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 ​ 2020 Balance at January 1 ​ $ 2,282 ​ $ 349 ​ $ 33 Provision recorded during the period ​ 526 ​ 2,043 ​ 431 Credits issued during the period ​ (2,024) ​ ​ (110) ​ ​ (115) Balance at December 31 ​ $ 784 ​ $ 2,282 ​ $ 349

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt
Schedule of long-term debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ As of ​ ​ ​ December 31, ​ ​ December 31, (in thousands) ​ 2022 ​ 2021 Term loan payable $ 2,079 $ 5,000 End of term fee ​ ​ 2,615 ​ ​ 2,331 Unamortized debt issuance costs ​ (55) ​ (145) Carrying value of term loan ​ ​ 4,639 ​ ​ 7,186 Other debt ​ ​ 582 ​ ​ 844 Less: Amounts due within one year ​ ​ (4,833) ​ ​ (3,765) Total long-term debt $ 388 $ 4,265 ​
Schedule of maturities of long-term debt	​ ​ ​ ​ ​ (in thousands) ​ ​ ​ 2023 ​ $ 5,006 2024 ​ $ 194 2025 ​ $ 194

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue
Summary of revenue by type	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, (in thousands) 2022 2021 2020 Product revenue, net ​ $ 34,742 ​ $ 23,386 ​ $ 108 Collaboration revenues ​ ​ 926 ​ ​ 3,830 ​ ​ 2,756 Research premium and grant revenue ​ ​ 1,267 ​ ​ 1,679 ​ ​ 2,163 Total revenues ​ $ 36,935 ​ $ 28,895 ​ $ 5,027 ​

Share Based Payments (Tables)

Share Based Payments (Tables)	12 Months Ended
	Dec. 31, 2022
Share Based Payments
Summary of information regarding stock option awards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Weighted ​ Average ​ ​ ​ ​ ​ ​ ​ average ​ Remaining ​ Aggregate ​ ​ ​ ​ exercise ​ Contractual ​ intrinsic ​ ​ ​ ​ price in ​ Term ​ value ​ ​ Options ​ $ per share ​ (in years) ​ (in thousands) Outstanding as of January 1, 2022 ​ 53,885 $ 510.34 ​ 8.0 ​ ​ — Granted ​ 24,160 ​ 11.25 ​ ​ ​ ​ — Exercised ​ — ​ — ​ ​ ​ ​ — Cancelled and forfeited ​ (2,172) ​ 323.43 ​ ​ ​ ​ — Outstanding as of December 31, 2022 ​ 75,873 $ 351.24 ​ 7.7 ​ $ — Vested and exercisable as of December 31, 2022 ​ 38,490 $ 653.81 ​ 6.6 ​ $ — ​
Summary of assumptions used for valuation of options	​ ​ ​ ​ ​ ​ ​ ​ Input parameters 2022 ​ 2021 ​ 2020 Range of expected volatility 76.4% - 76.9% ​ 75.3% ‑ 77.3% ​ 63.7% ‑ 74.4% Expected term of options (in years) 6.1 ​ 5.5 - 6.1 ​ 5.5 - 6.1 Range of risk-free interest rate 1.7% - 1.8% ​ 0.8% ‑ 1.3% ​ 0.8% ‑ 1.5% Dividend yield — ​ — ​ – ​
Summary of information regarding restricted stock awards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ average grant date fair ​ RSUs ​ ​ value in $ per share Outstanding as of January 1, 2022 31,538 ​ $ 74.10 Granted 19,566 ​ ​ 11.04 Vested and issued (9,512) ​ ​ 85.25 Forfeited (2,957) ​ ​ 41.72 Outstanding as of December 31, 2022 38,635 ​ $ 41.89 ​
Schedule of allocation of share-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, (in thousands) 2022 2021 2020 Research and development expense $ 123 ​ $ 565 ​ $ 1,280 Selling, general and administrative expense ​ 1,844 ​ ​ 2,726 ​ ​ 3,939 Total stock-based compensation expense $ 1,967 ​ $ 3,291 ​ $ 5,219 ​

Income Tax Expense (Tables)

Income Tax Expense (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Expense
Schedule of loss before income taxes attributable to domestic and international operations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 (in thousands) 2022 2021 2020 Domestic ​ $ (54,235) ​ $ (40,540) ​ $ (71,344) Foreign ​ (1,382) ​ (8,420) ​ 1,999 Loss before income taxes ​ $ (55,617) ​ $ (48,960) ​ $ (69,345) ​
Schedule of income tax expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 (in thousands) 2022 2021 2020 Current tax ​ ​ ​ ​ ​ ​ ​ ​ ​ Domestic ​ $ (1) ​ $ — ​ $ — Foreign ​ (1,567) ​ (490) ​ (139) Deferred tax ​ ​ ​ ​ ​ ​ ​ ​ ​ Domestic ​ ​ ​ — ​ — Foreign ​ ​ ​ — ​ — Total income tax expense ​ $ (1,568) ​ $ (490) ​ $ (139) ​
Schedule of effective income tax rate reconciliation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 ​ (% of pre-tax income) 2022 2021 2020 ​ Statutory income tax rate 12.5 % 12.5 % 12.5 % Income not subject to tax 0.3 ​ 0.4 ​ 0.2 ​ Tax credits 0.6 ​ 0.0 ​ 0.6 ​ Foreign operations ​ (8.1) ​ (7.3) ​ 3.0 ​ Other 0.3 ​ (1.7) ​ 2.3 ​ Valuation allowance (8.4) ​ (4.9) ​ (18.8) ​ Effective income tax rate (2.8) % (1.0) % (0.2) % ​
Summary of the components of deferred income tax balances	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands) 2022 2021 Deferred tax assets: ​ ​ ​ ​ Net operating loss carryforwards ​ $ 116,080 ​ $ 111,220 Tax loss on liquidation of subsidiary ​ ​ 1,184 ​ ​ 2,501 Equity compensation ​ 4,258 ​ 4,067 Non-deductible reserves ​ 2,118 ​ 905 Total deferred tax assets ​ ​ 123,640 ​ ​ 118,693 Valuation allowance ​ (123,277) ​ (118,583) Net deferred tax assets ​ ​ 363 ​ ​ 110 Deferred tax liabilities: ​ ​ ​ ​ ​ ​ Financial liabilities ​ ​ 363 ​ 100 Property and equipment ​ — ​ 10 Total deferred tax liability ​ ​ 363 ​ ​ 110 Deferred tax, net ​ $ — ​ $ — ​
Summary of changes in the deferred tax valuation allowance	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands) 2022 2021 2020 Balance at beginning of year $ (118,583) $ (116,200) $ (103,185) Tax benefit ​ (4,694) ​ (2,383) ​ (13,015) Balance at end of year ​ $ (123,277) $ (118,583) $ (116,200) ​
Summary of carryforwards of net operating losses	​ ​ ​ ​ ​ ​ ​ (in thousands) Amount Expiration Ireland ​ $ 350,597 Indefinite Austria ​ $ 232,679 Indefinite United States ​ $ 10,403 ​ Indefinite United States ​ $ 35,246 2033 ​

Earnings (Loss) per Share (Tabl

Earnings (Loss) per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings (Loss) per Share
Schedule of basic and diluted loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands, except share and per share data) 2022 2021 2020 Net loss for the period ​ $ (57,185) ​ $ (49,450) ​ $ (69,484) Weighted average number of shares outstanding ​ 2,681,968 ​ 1,733,978 ​ 513,804 Basic and diluted loss per share ​ $ (21.32) ​ $ (28.52) ​ $ (135.23) ​
Schedule of ordinary share equivalents excluded from the calculations of diluted loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 ​ 2022 2021 2020 Stock option awards ​ 75,873 ​ 53,939 ​ 42,113 Restricted share units ​ 38,635 ​ 31,589 ​ 9,575 Warrants ​ 262,384 ​ 424,773 ​ 217,553

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies
Schedule of future minimum contractual obligations and commitments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ending December 31, (in thousands) Total 2023 2024 2025 2026 2027 Thereafter Operating lease obligations ​ $ 892 ​ ​ 892 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ $ — XENLETA API purchase ​ ​ 39,145 ​ ​ 3,317 ​ ​ 3,317 ​ ​ 4,704 ​ ​ 4,704 ​ ​ 4,704 ​ ​ 18,399 Other contractual commitments ​ 5,965 ​ 3,729 ​ 1,360 ​ 876 ​ — ​ — ​ — Total contractual commitments and contingencies ​ $ 46,002 ​ $ 7,938 ​ $ 4,677 ​ $ 5,580 ​ $ 4,704 ​ $ 4,704 ​ $ 18,399 ​

Organization and Business Act_2

Organization and Business Activities (Details)

1 Months Ended

12 Months Ended

Apr. 15, 2023 USD ($)

Jan. 02, 2023 USD ($)

Sep. 30, 2021 USD ($) $ / shares shares

May 31, 2021 USD ($)

Mar. 31, 2021 USD ($) $ / shares shares

Dec. 31, 2020 USD ($) $ / shares shares

May 31, 2020 USD ($) $ / shares shares

Dec. 31, 2022 USD ($) shares

Dec. 31, 2021 USD ($)

Dec. 31, 2020 USD ($) $ / shares

Jul. 13, 2022 country

Dec. 31, 2019 USD ($)

Liquidity

Number of countries, exclusive rights are distributed. | country

9

Number of additional countries rights are distributed | country

5

Cash and cash equivalents and restricted cash

$ 41,590,000

$ 12,537,000

$ 47,834,000

$ 41,590,000

$ 86,411,000

Proceeds from at-the-market facility

3,460,000

42,280,000

7,520,000

Shares issued

5,584,000

$ 70,138,000

$ 61,060,000

Public offering

Liquidity

Number of shares issued | shares

240,000

Shares Issued, Price Per Share | $ / shares

$ 62.50

$ 62.50

Proceeds from at-the-market facility

$ 15,000,000

Net proceeds from sale of stock

$ 13,300,000

Purchase agreement

Liquidity

Number of shares issued | shares

165,755

Proceeds from at-the-market facility

$ 38,000,000

Net proceeds from sale of stock

$ 35,200,000

Number of ordinary shares that can be purchased by warrant holders | shares

165,755

Share and warrant price | $ / shares

$ 229.21

Purchasers | Purchase agreement

Liquidity

Number of shares issued | shares

390,440

Net proceeds from sale of stock

$ 23,400,000

Proceeds from Issuance or Sale of Equity

$ 25,400,000

Number of ordinary shares that can be purchased by warrant holders | shares

195,220

Term

5 years

Lincoln Park Capital Fund, LLC | Purchase agreement

Liquidity

Net proceeds from sale of stock

$ 4,600,000

Lincoln Park Capital Fund, LLC | Purchase agreement | Maximum

Liquidity

Ordinary shares remained unsold

$ 18,500,000

Lincoln Park Capital Fund, LLC | Purchase agreement | Ordinary shares

Liquidity

Number of shares issued | shares

320,000

Net proceeds from sale of stock

$ 4,600,000

Commitment shares | shares

25,298

Commitment share price | $ / shares

$ 0.01

Regular purchase

$ 2,500,000

Lincoln Park Capital Fund, LLC | Purchase agreement | Ordinary shares | Minimum

Liquidity

Shares issued

200,000

Lincoln Park Capital Fund, LLC | Purchase agreement | Ordinary shares | Maximum

Liquidity

Shares issued

$ 23,000,000

Lincoln Park Capital Fund, LLC | Purchase agreement | Ordinary shares | Share Price Not Below $0.25 Per Share

Liquidity

Share price | $ / shares

$ 0.25

Lincoln Park Capital Fund, LLC | Purchase agreement | Ordinary shares | Share Price Not Below $0.25 Per Share | Maximum

Liquidity

Number of shares issued | shares

16,000

Lincoln Park Capital Fund, LLC | Purchase agreement | Ordinary shares | Share Price Not Below $2.00 Per Share

Liquidity

Share price | $ / shares

$ 50

Lincoln Park Capital Fund, LLC | Purchase agreement | Ordinary shares | Share Price Not Below $2.00 Per Share | Maximum

Liquidity

Number of shares issued | shares

24,000

Lincoln Park Capital Fund, LLC | Purchase agreement | Ordinary shares | Share Price Not Below $3.00 Per Share

Liquidity

Share price | $ / shares

$ 75

Lincoln Park Capital Fund, LLC | Purchase agreement | Ordinary shares | Share Price Not Below $3.00 Per Share | Maximum

Liquidity

Number of shares issued | shares

32,000

Ordinary Share Warrants | Purchasers | Purchase agreement

Liquidity

Number of ordinary shares that can be purchased by warrant holders | shares

24,000

Share and warrant price | $ / shares

$ 61.31

Exercise price | $ / shares

$ 59.75

Pre-Funded Warrants | Purchasers | Purchase agreement

Liquidity

Number of ordinary shares that can be purchased by warrant holders | shares

12,000

Share and warrant price | $ / shares

$ 61.06

Exercise price | $ / shares

$ 0.01

Open Market Sale Agreement | Jefferies LLC | Ordinary shares

Liquidity

Number of shares issued | shares

1,429,729

Proceeds from at-the-market facility

$ 32,500,000

Aggregate gross sale proceeds for ordinary shares

$ 33,900,000

Open Market Sale Agreement | Jefferies LLC | Ordinary shares | Maximum

Liquidity

Aggregate gross sale proceeds for ordinary shares

$ 50,000,000

Subsequent Event | Lincoln Park Capital Fund, LLC | Purchase agreement | Maximum

Liquidity

Ordinary shares remained unsold

$ 18,500,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Reverse Stock Split (Details)	Sep. 16, 2022 shares
Summary of Significant Accounting Policies
Conversion ratio of common stock to ordinary shares	0.04%
Fractional shares	0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Summary of Significant Accounting Policies
Total inventory	$ 9,676	$ 14,509
Inventory valuation reserves	5,200	300
Prepaid inventory	900
XENLETA
Summary of Significant Accounting Policies
Raw materials	916	1,528
Work in process	4,658	9,142
Finished goods	640	18
Total inventory	6,214	10,688
Obsolete inventory non-cash reserve	5,600
SIVEXTRO
Summary of Significant Accounting Policies
Finished goods	3,462	$ 3,821
Inventory valuation reserves	$ 0

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2022
IT equipment | Minimum
Property, Plant and Equipment
Estimated useful life of property and equipment	3 years
IT equipment | Maximum
Property, Plant and Equipment
Estimated useful life of property and equipment	5 years
Laboratory equipment | Minimum
Property, Plant and Equipment
Estimated useful life of property and equipment	5 years
Laboratory equipment | Maximum
Property, Plant and Equipment
Estimated useful life of property and equipment	10 years
Other equipment | Minimum
Property, Plant and Equipment
Estimated useful life of property and equipment	3 years
Other equipment | Maximum
Property, Plant and Equipment
Estimated useful life of property and equipment	10 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Intangible Assets and Other Long-lived Assets and Segment Information (Details)	12 Months Ended
	Dec. 31, 2022 segment
Intangible assets
Number of operating segments	1
Minimum
Intangible assets
Estimated useful life of intangible assets	3 years
Maximum
Intangible assets
Estimated useful life of intangible assets	10 years

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Short-term investments:
Transfer of assets from Level 1 to 2	$ 0	$ 0
Transfer of liabilities from Level 1 to 2	0	0
Transfer of liabilities from Level 2 to 1	$ 0	0
Recurring
Cash equivalent:
Money market fund		8,050
Short-term investments:
Term deposits		16
Total assets		8,066
Level 1 | Recurring
Cash equivalent:
Money market fund		8,050
Short-term investments:
Term deposits		16
Total assets		$ 8,066

Accounts Receivable, net and _3

Accounts Receivable, net and Other Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Other receivables
Receivables from customers, net	$ 3,208	$ 8,778
Receivables from collaborative arrangements	274	2,193
Research premium	2,472	1,237
Other receivables	788	543
Total accounts receivable, net and other receivables	$ 6,742	$ 12,751

Accounts Receivable, net and _4

Accounts Receivable, net and Other Receivables - Product Revenue Allowances and Reserves (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accounts Receivable, net and Other Receivables
Receivables from customers	$ 5,168	$ 10,149
Less: fee for service	(832)	(924)
Less: chargeback reserve	(902)	(249)
Less: cash discount	(226)	(198)
Receivables from customers, net	$ 3,208	$ 8,778

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment
Property, plant and equipment, gross	$ 4,799	$ 4,588
Less: Accumulated depreciation	(4,519)	(4,355)
Property and equipment, net	280	233
IT equipment
Property, Plant and Equipment
Property, plant and equipment, gross	1,095	1,083
Laboratory equipment
Property, Plant and Equipment
Property, plant and equipment, gross	3,604	3,404
Other equipment
Property, Plant and Equipment
Property, plant and equipment, gross	$ 100	$ 101

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accrued expenses and other liabilities
Research and development related costs	$ 707	$ 789
Payroll and related costs	1,737	5,085
Accounting, tax and audit services	552	736
Manufacturing and inventory	8,113	592
Product returns	784	2,282	$ 349	$ 33
Government rebates	2,028	1,751
Other accrued gross to net	2,129	1,090
Other	1,291	1,504
Total accrued expenses and other current liabilities	17,341	$ 13,829
Other contractual commitments	5,965
Accrued expense and other current liabilities
Accrued expenses and other liabilities
Other contractual commitments	$ 4,300

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities - Reserve for Product Returns (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accrued Expenses and Other Current Liabilities
Balance at beginning	$ 2,282	$ 349	$ 33
Provision recorded during the period	526	2,043	431
Credits issued during the period	(2,024)	(110)	(115)
Balance at ending	$ 784	$ 2,282	$ 349

Debt - Summary (Details)

Debt - Summary (Details) - USD ($)					1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 05, 2023	Sep. 22, 2022	Jun. 02, 2021	Mar. 11, 2020	Feb. 29, 2020	Mar. 31, 2020	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2018
Debt
Loss on extinguishment of debt								$ (2,757,000)
Term loan
Debt
End of term fee							$ 2,079,000		$ 5,000,000
Loan Agreement | Term loan
Debt
Maximum borrowing capacity										$ 75,000,000
Principal amount of advances outstanding				$ 35,000,000
Interest rate (as a percent)							9.80%
Fee due at maturity, as a percentage of aggregate advances							6.95%
The amount in excess of which prepayments may be made							$ 5,000,000
Repayment of debt				$ 30,000,000			30,000,000
Minimum cash and cash equivalents in accounts to be maintained			$ 3,000,000
Net product revenue			$ 15,000,000
Trailing period			3 months		6 months
Percent of net product revenue sales target				70%	80%
Minimum liquidity requirement					$ 40,000,000
Minimum amount to be maintained in cash and cash equivalents				$ 3,000,000
End of term loan charge payment				2,100,000
End of term loan charge				$ 300,000	$ 600,000
Loan origination costs							1,300,000
Initial fee paid to lender							700,000
Loss on extinguishment of debt						$ 2,700,000
End of term fee							$ 2,100,000
Loan Agreement | Term loan | Subsequent Event
Debt
Repayment of debt	$ 4,500,000
Loan Agreement | Term loan | Prime rate
Debt
Variable interest rate margin (as a percent)							9.80%
Variable rate adjustment (as a percent)							5.50%
Reference rate for effective interest rate (as percent)		6.25%
Loan Agreement | Term loan | Initial Advance
Debt
Principal amount of advances outstanding										$ 25,000,000
Loan Agreement | Term loan | Tranche 7 Advance
Debt
Additional tranches							$ 10,000,000
Loan Agreement | Term loan | Prepayment during the first 12 months following initial closing
Debt
Prepayment penalty as a percentage of the amount being repaid							3%
Loan Agreement | Term loan | Prepayment after the first 12 months following initial closing but before 24 months
Debt
Prepayment penalty as a percentage of the amount being repaid							2%
Loan Agreement | Term loan | Prepayment after the first 24 months following initial closing but before maturity
Debt
Prepayment penalty as a percentage of the amount being repaid							1%
Hercules Capital Inc | Loan Agreement | Term loan
Debt
Interest rate (as a percent)		10.55%

Debt - Long-Term Debt (Details)

Debt - Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Long-term debt
Less: Amounts due within one year	$ (4,833)	$ (3,765)
Long-term debt	388	4,265
Maturities of long-term debt
2023	5,006
2024	194
2025	194
Term loan
Long-term debt
Term loan payable	2,079	5,000
End of term fee	2,615	2,331
Unamortized debt issuance costs	(55)	(145)
Carrying value of term loan	4,639	7,186
Other debt
Long-term debt
Carrying value of term loan	$ 582	$ 844

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)			1 Months Ended					12 Months Ended
	Apr. 15, 2023	Jan. 02, 2023	Sep. 30, 2021	May 31, 2021	Mar. 31, 2021	Dec. 31, 2020	May 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stockholders' Equity
Net proceeds for deducting commissions and offering expenses payable								$ 3,460,000	$ 42,280,000	$ 7,520,000
Shares issued								$ 5,584,000	$ 70,138,000	$ 61,060,000
Nominal value								$ 0.01	$ 0.01
Public offering
Stockholders' Equity
Number of shares issued						240,000
Shares issued, price per share						$ 62.50				$ 62.50
Net proceeds for deducting commissions and offering expenses payable						$ 15,000,000
Net proceeds from sale of stock						$ 13,300,000
Purchase agreement
Stockholders' Equity
Number of shares issued							165,755
Number of ordinary shares that can be purchased by warrant holders							165,755
Share and warrant price							$ 229.21
Net proceeds for deducting commissions and offering expenses payable							$ 38,000,000
Net proceeds from sale of stock							$ 35,200,000
Purchasers | Warrants Issued In May 2020
Stockholders' Equity
Warrants outstanding								0
Purchasers | Purchase agreement
Stockholders' Equity
Number of shares issued					390,440
Number of ordinary shares that can be purchased by warrant holders					195,220
Term					5 years
Net proceeds from sale of stock					$ 23,400,000
Gross proceeds from public offering					$ 25,400,000
Nominal value					$ 0.01
Purchasers | Purchase agreement | Warrants Issued In May 2020
Stockholders' Equity
Term								2 years
Purchasers | Purchase agreement | Ordinary Share Warrants
Stockholders' Equity
Number of ordinary shares that can be purchased by warrant holders					24,000
Share and warrant price					$ 61.31
Per share exercise price of right					$ 59.75
Purchasers | Purchase agreement | Pre-Funded Warrants
Stockholders' Equity
Number of ordinary shares that can be purchased by warrant holders					12,000
Share and warrant price					$ 61.06
Per share exercise price of right					$ 0.01
Lincoln Park Capital Fund, LLC | Purchase agreement
Stockholders' Equity
Net proceeds from sale of stock								$ 4,600,000
Lincoln Park Capital Fund, LLC | Purchase agreement | Maximum
Stockholders' Equity
Ordinary shares remained unsold		$ 18,500,000
Lincoln Park Capital Fund, LLC | Purchase agreement | Ordinary shares
Stockholders' Equity
Number of shares issued								320,000
Net proceeds from sale of stock								$ 4,600,000
Commitment shares			25,298
Commitment share price			$ 0.01
Regular purchase			$ 2,500,000
Lincoln Park Capital Fund, LLC | Purchase agreement | Ordinary shares | Maximum
Stockholders' Equity
Shares issued			23,000,000
Lincoln Park Capital Fund, LLC | Purchase agreement | Ordinary shares | Minimum
Stockholders' Equity
Shares issued			$ 200,000
Lincoln Park Capital Fund, LLC | Purchase agreement | Share Price Not Below $0.25 Per Share | Ordinary shares
Stockholders' Equity
Share price			$ 0.25
Lincoln Park Capital Fund, LLC | Purchase agreement | Share Price Not Below $0.25 Per Share | Ordinary shares | Maximum
Stockholders' Equity
Number of shares issued			16,000
Lincoln Park Capital Fund, LLC | Purchase agreement | Share Price Not Below $2.00 Per Share | Ordinary shares
Stockholders' Equity
Share price			$ 50
Lincoln Park Capital Fund, LLC | Purchase agreement | Share Price Not Below $2.00 Per Share | Ordinary shares | Maximum
Stockholders' Equity
Number of shares issued			24,000
Lincoln Park Capital Fund, LLC | Purchase agreement | Share Price Not Below $3.00 Per Share | Ordinary shares
Stockholders' Equity
Share price			$ 75
Lincoln Park Capital Fund, LLC | Purchase agreement | Share Price Not Below $3.00 Per Share | Ordinary shares | Maximum
Stockholders' Equity
Number of shares issued			32,000
Open Market Sale Agreement | Jefferies LLC | Ordinary shares
Stockholders' Equity
Number of shares issued								1,429,729
Net proceeds for deducting commissions and offering expenses payable								$ 32,500,000
Aggregate gross sale proceeds for ordinary shares								$ 33,900,000
Open Market Sale Agreement | Jefferies LLC | Ordinary shares | Maximum
Stockholders' Equity
Aggregate gross sale proceeds for ordinary shares				$ 50,000,000
Subsequent Event | Lincoln Park Capital Fund, LLC | Purchase agreement | Maximum
Stockholders' Equity
Ordinary shares remained unsold	$ 18,500,000

Revenue (Details)

Revenue (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2020	Mar. 31, 2019	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue
Revenue accounted for under Topic 606				$ 36,935	$ 28,895	$ 5,027
Sinovant Sciences, LTD | License Agreement
Revenue
Regulatory milestone payment received						500
Merck & Co | License Agreement
Revenue
Revenue accounted for under Topic 606					1,200
Regulatory milestone payment received						1,800
Product revenue, net
Revenue
Revenue accounted for under Topic 606				34,742	23,386	108
Collaboration revenue
Revenue
Revenue accounted for under Topic 606				926	3,830	2,756
Collaboration revenue | Sumitomo Pharmaceuticals (Suzhou) | License Agreement
Revenue
Revenue accounted for under Topic 606				900	2,600
Collaboration revenue - Upfront payment | Sumitomo Pharmaceuticals (Suzhou) | License Agreement
Revenue
Revenue accounted for under Topic 606	$ 3,000	$ 1,000	$ 5,000
Research premium and grant revenue
Revenue
Revenue accounted for under Topic 606				$ 1,267	$ 1,679	$ 2,163

Revenue - Summary of Gross-To-N

Revenue - Summary of Gross-To-Net ("GTN") Adjustments (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Product revenue, gross	$ 8,000	$ 17,000
XENLETA
Disaggregation of Revenue [Line Items]
GTN accrual adjustments	200,000	(400,000)	$ 100,000
Returns reserve & GTN accrual adjustments	300,000	$ 1,300,000
Percentage of inventory held		50%
SIVEXTRO
Disaggregation of Revenue [Line Items]
GTN accrual adjustments	$ 34,500,000	$ 23,800,000

Share Based Payments - Stock Pl

Share Based Payments - Stock Plan Activity (Details) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2018 $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2020 tranche	Dec. 31, 2019 USD ($)	Dec. 31, 2018 tranche	Sep. 30, 2021 shares	Aug. 31, 2021 shares	Mar. 04, 2021 shares	Dec. 09, 2020 shares	Mar. 12, 2019 shares
Share-Based Payments
Share-based compensation expense | $		$ 1,967	$ 3,291		$ 5,219
Stock Options
Share-Based Payments
Options granted during the period		24,160
Options exercise price (in dollars per share) | $ / shares		$ 351.24	$ 510.34
Restricted Share Units ("RSUs")
Share-Based Payments
Restricted stock granted during the period		19,566
Stock Option Plan 2015 | Stock Options
Share-Based Payments
Vesting period		4 years
Stock Option Plan 2015 | Stock Options | Vesting period, year one
Share-Based Payments
Percentage that vests during the period		25%
Stock Option Plan 2015 | Stock Options | Vesting period, years 2-4
Share-Based Payments
Percentage that vests during the period		75%
Monthly vesting percentage		2.083%
Stock Option Plan 2015 | Maximum | Stock Options
Share-Based Payments
Exercise period		10 years
2017 Share Incentive Plan | Restricted Share Units ("RSUs")
Share-Based Payments
Vesting period		4 years
Percentage that vests during the period		25%
2017 Share Incentive Plan | Restricted Share Units ("RSUs") | XENLETA
Share-Based Payments
Vesting period						6 months
Number of vesting periods | tranche						3
2017 Share Incentive Plan | Restricted Share Units ("RSUs") | Immediate vesting upon regulatory approval | XENLETA
Share-Based Payments
Percentage that vests during the period						50%
2017 Share Incentive Plan | Restricted Share Units ("RSUs") | Immediate vesting upon regulatory approval | CONTEPO
Share-Based Payments
Percentage that vests during the period						50%
2017 Share Incentive Plan | Restricted Share Units ("RSUs") | Vesting upon the one-year-anniversary of FDA approval | XENLETA
Share-Based Payments
Percentage that vests during the period						50%
2017 Share Incentive Plan | Restricted Share Units ("RSUs") | Vesting upon the one-year-anniversary of FDA approval | CONTEPO
Share-Based Payments
Percentage that vests during the period						50%
2019 Inducement Plan | Ordinary shares
Share-Based Payments
Shares reserved for future issuance											8,000
Inducement Awards Outside of the 2019 Inducement Plan | Vesting period, year one
Share-Based Payments
Percentage that vests during the period	25%
Inducement Awards Outside of the 2019 Inducement Plan | Vesting period, year two
Share-Based Payments
Percentage that vests during the period	75%
Monthly vesting period	36 months
Inducement Awards Outside of the 2019 Inducement Plan | Restricted Share Units ("RSUs") | Chief Executive Officer
Share-Based Payments
Options granted during the period	600
Inducement Awards Outside of the 2019 Inducement Plan | Restricted Share Units ("RSUs") | Upon receipt of FDA approval
Share-Based Payments
Percentage that vests during the period	50%
Inducement Awards Outside of the 2019 Inducement Plan | Restricted Share Units ("RSUs") | First anniversary of FDA approval
Share-Based Payments
Percentage that vests during the period	50%
Inducement Awards Outside of the 2019 Inducement Plan | Non-statutory option
Share-Based Payments
Vesting period	4 years
Exercise period	10 years
Options exercise price (in dollars per share) | $ / shares	$ 882.50
Inducement Awards Outside of the 2019 Inducement Plan | Non-statutory option | Chief Executive Officer
Share-Based Payments
Options granted during the period	3,400
2020 Share Incentive Plan | Restricted Share Units ("RSUs") | Chief Executive Officer
Share-Based Payments
Percentage that vests during the period		50%
Restricted stock granted during the period		280
2020 Share Incentive Plan | Restricted Share Units ("RSUs") | Employees
Share-Based Payments
Vesting period				6 months
Number of vesting periods | tranche				3
2020 Share Incentive Plan | Ordinary shares
Share-Based Payments
Shares reserved for future issuance		12,788
2020 Share Incentive Plan | Ordinary shares | Maximum
Share-Based Payments
Shares reserved for future issuance									37,200
2021 Inducement Share Incentive Plan | Maximum
Share-Based Payments
Term of Awards		ten years
2021 Inducement Share Incentive Plan | Ordinary shares
Share-Based Payments
Shares reserved for future issuance							20,000	8,000		8,000

Share Based Payments - Stock Op

Share Based Payments - Stock Options (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value Assumptions
Expected term of options (in years)	6 years 1 month 6 days
Dividend yield	0%	0%	0%
Minimum
Fair Value Assumptions
Expected volatility	76.40%	75.30%	63.70%
Expected term of options (in years)		5 years 6 months	5 years 6 months
Range of risk-free interest rate	1.70%	0.80%	0.80%
Maximum
Fair Value Assumptions
Expected volatility	76.90%	77.30%	74.40%
Expected term of options (in years)		6 years 1 month 6 days	6 years 1 month 6 days
Range of risk-free interest rate	1.80%	1.30%	1.50%
Stock Options
Options
Outstanding at beginning of year (in shares)	53,885
Granted (in shares)	24,160
Cancelled and forfeited (in shares)	(2,172)
Outstanding at end of year (in shares)	75,873	53,885
Vested and exercisable at end of year (in shares)	38,490
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)	$ 510.34
Granted (in dollars per share)	11.25
Cancelled and forfeited (in dollars per share)	323.43
Outstanding balance at end of year (in dollars per share)	351.24	$ 510.34
Vested and exercisable balance at end of year (in dollars per share)	$ 653.81
Weighted Average Remaining Contractual Term (in years)
Weighted average remaining contractual term, outstanding	7 years 8 months 12 days	8 years
Weighted average remaining contractual term, vested and exercisable	6 years 7 months 6 days
Additional disclosures
Total unrecognized compensation related to unvested options	$ 0.7
Recognition period	1 month 6 days
Weighted-average grant date fair value (in dollars per share)	$ 11.05	$ 20.53	$ 149.84
Stock Options | Exercise Price Range From 1.06 To 110.0 [Member]
Additional disclosures
Exercise price maximum range	2,750
Exercise price minimum range	$ 11.25
Stock Options | Minimum
Fair Value Assumptions
Risk-free interest rate average market yield term	5 years
Stock Options | Maximum
Fair Value Assumptions
Risk-free interest rate average market yield term	7 years

Share Based Payments - Restrict

Share Based Payments - Restricted Stock Units (Details) - Restricted Share Units ("RSUs") - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restricted Stock Units
Number of shares outstanding	31,538
Granted	19,566
Vested and issued	(9,512)
Forfeited	(2,957)
Number of shares outstanding	38,635	31,538
Weighted average grant date fair value per share
Weighted average grant date fair value per share at the beginning	$ 74.10
Granted	11.04
Vested and issued	85.25
Forfeited	41.72
Weighted average grant date fair value per share at the end	$ 41.89	$ 74.10
Additional disclosures
Total unrecognized compensation related to unvested RSUs	$ 0.5
Recognition period	1 month 6 days
Fair Value	$ 0.1	$ 0.2	$ 0.4

Share Based Payments - Stock-ba

Share Based Payments - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019
Share-Based Payments
Share-based compensation expense	$ 1,967	$ 3,291	$ 5,219
Research and development
Share-Based Payments
Share-based compensation expense	123	565	1,280
Selling, general and administrative
Share-Based Payments
Share-based compensation expense	$ 1,844	$ 2,726	$ 3,939

Share Based Payments - Employee

Share Based Payments - Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan - shares	1 Months Ended	12 Months Ended
	Aug. 31, 2018	Dec. 31, 2022
Share-Based Payments
Maximum number of shares authorized under plan (in shares)	2,000
Purchase discount as a percentage of current market price		15%

Post-employment Benefit Oblig_2

Post-employment Benefit Obligations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Austria
Post-employment Benefit Obligations
Employer monthly contribution (as a percent)	1.53%	1.53%	1.53%
Contribution costs	$ 49,000	$ 56,000	$ 57,000
U.S.
Post-employment Benefit Obligations
Contribution costs	$ 383,000	$ 360,000	$ 396,000
Percent of match, first level	100%	100%	100%
Employee voluntary contribution, first level	3%	3%	3%
Percent match, second level	50%	50%	50%
Employee voluntary contribution, second level	2%	2%	2%

Income Tax Expense - Components

Income Tax Expense - Components (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Loss before income taxes attributable to domestic and international operations
Domestic	$ (54,235)	$ (40,540)	$ (71,344)
Foreign	(1,382)	(8,420)	1,999
Loss before income taxes	(55,617)	(48,960)	(69,345)
Current tax
Domestic	(1)
Foreign	(1,567)	(490)	(139)
Total income tax expense	$ (1,568)	$ (490)	$ (139)
Effective income tax reconciliation
Statutory income tax rate	12.50%	12.50%	12.50%
Income not subject to tax	0.30%	0.40%	0.20%
Tax credits	0.60%	0%	0.60%
Foreign operations	(8.10%)	(7.30%)	3%
Other	0.30%	(1.70%)	2.30%
Valuation allowance	(8.40%)	(4.90%)	(18.80%)
Effective income tax rate	(2.80%)	(1.00%)	(0.20%)
Ireland
Effective income tax reconciliation
Statutory income tax rate	12.50%	12.50%	12.50%

Income Tax Expense (Details)

Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Expense
Income tax expense (benefit)	$ 1,568	$ 490	$ 139
Valuation allowance - current and noncurrent	$ 123,277	$ 118,583	$ 116,200	$ 103,185

Income Tax Expense - Deferred I

Income Tax Expense - Deferred Income Tax (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating loss carryforwards	$ 116,080	$ 111,220
Tax loss on liquidation of subsidiary	1,184	2,501
Equity compensation	4,258	4,067
Non-deductible reserves	2,118	905
Total deferred tax assets	123,640	118,693
Valuation allowance	(123,277)	(118,583)	$ (116,200)	$ (103,185)
Net deferred tax assets	363	110
Deferred tax liabilities:
Financial liabilities	363	100
Property and equipment		10
Total deferred tax liability	363	110
Deferred tax, net	$ 0	$ 0

Income Tax Expense - Valuation

Income Tax Expense - Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income tax (expense) benefit
Balance at beginning of year	$ (118,583)	$ (116,200)	$ (103,185)
Balance at end of year	(123,277)	(118,583)	(116,200)
Tax benefit
Income tax (expense) benefit
Change in valuation allowance	$ (4,694)	$ (2,383)	$ (13,015)

Income Tax Expense - Net Operat

Income Tax Expense - Net Operating Losses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net operating losses carryforwards
Period in which the company is in cumulative loss position.	3 years
Valuation allowance	$ 123,277	$ 118,583	$ 116,200	$ 103,185
Uncertain tax positions disclosures
Uncertain tax positions	0
Ireland
Net operating losses carryforwards
Net operating losses carryforwards	350,597
Austria
Net operating losses carryforwards
Net operating losses carryforwards	232,679
U.S.
Net operating losses carryforwards
Net operating losses carryforwards	10,403
Net operating losses carryforwards	$ 35,246

Earnings (Loss) per Share - Bas

Earnings (Loss) per Share - Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Basic and Diluted Loss per Share
Net loss for the period	$ (57,185)	$ (49,450)	$ (69,484)
Weighted average number of shares outstanding, Basic	2,681,968	1,733,978	513,804
Weighted average number of shares outstanding, Diluted	2,681,968	1,733,978	513,804
Basic loss ($ per share)	$ (21.32)	$ (28.52)	$ (135.23)
Diluted loss ($ per share)	$ (21.32)	$ (28.52)	$ (135.23)

Earnings (Loss) per Share - Ant

Earnings (Loss) per Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stock Options
Anti-dilutive stock options
Ordinary share equivalents excluded from the calculations of diluted earnings per share	75,873	53,939	42,113
Restricted Share Units ("RSUs")
Anti-dilutive stock options
Ordinary share equivalents excluded from the calculations of diluted earnings per share	38,635	31,589	9,575
Warrants
Anti-dilutive stock options
Ordinary share equivalents excluded from the calculations of diluted earnings per share	262,384	424,773	217,553

Significant Arrangements and _2

Significant Arrangements and License Agreements (Details) $ in Thousands

1 Months Ended

3 Months Ended

12 Months Ended

Apr. 12, 2021

Jul. 10, 2020 USD ($)

Dec. 31, 2020 USD ($)

Mar. 31, 2018 USD ($)

Mar. 31, 2021 USD ($)

Dec. 31, 2020 USD ($)

Sep. 30, 2019 USD ($)

Mar. 31, 2019 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Dec. 31, 2020 USD ($)

Jul. 13, 2022 country

May 31, 2021 USD ($)

License Agreement

Number of countries, exclusive rights are distributed. | country

9

Number of additional countries rights are distributed | country

5

Revenue accounted for under Topic 606

$ 36,935

$ 28,895

$ 5,027

SIVEXTRO

License Agreement

Percentage of net product sales recognized

100%

Sunovion Pharmaceutics Canada, Inc. | Collaboration revenue - Upfront payment

License Agreement

Revenue accounted for under Topic 606

$ 1,000

License Agreement | Sunovion Pharmaceutics Canada, Inc. | NDS Approval

License Agreement

Revenue accounted for under Topic 606

$ 500

License Agreement | Sumitomo Pharmaceuticals (Suzhou)

License Agreement

Upfront payment

$ 5,000

Notice period for termination of agreement

180 days

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | Achievement of certain regulatory and commercial milestones

License Agreement

Maximum contingent milestone payment

91,500

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | Subsequent regulatory approval

License Agreement

Maximum contingent milestone payment

$ 4,000

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | Clinical trial application submission

License Agreement

Proceeds from license agreement, milestone

$ 1,500

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | FDA approval

License Agreement

Revenue accounted for under Topic 606

$ 5,000

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | Approval of XENLETA

License Agreement

Revenue accounted for under Topic 606

$ 5,000

Remaining probable of achieving

1,000

Additional revenue recognized

3,000

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | Additional regulatory approvals and annual sales targets

License Agreement

Remaining milestone payments

$ 86,000

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | Collaboration revenue - Upfront payment

License Agreement

Revenue accounted for under Topic 606

$ 3,000

$ 1,000

$ 5,000

Milestone achieved

$ 1,000

Performance obligation

$ 600

$ 2,400

Commitments and Contingencies -

Commitments and Contingencies - Additional Lease Disclosures and Other Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Future payments of operating lease liabilities, ASC 842
2023	$ 892
Total	892
XENLETA API purchase
Total	39,145
2023	3,317
2024	3,317
2025	4,704
2026	4,704
2027	4,704
Thereafter	18,399
Other contractual commitments
Total	5,965
2023	3,729
2024	1,360
2025	876
Future minimum contractual obligations and commitments
Total contractual commitments and contingencies	46,002
2023	7,938
2024	4,677
2025	5,580
2026	4,704
2027	4,704
Thereafter	18,399
Accrued expense and other current liabilities
Other contractual commitments
Total	4,300
Future minimum contractual obligations and commitments
Total contractual commitments and contingencies	$ 4,300

Commitments and Contingencies_2

Commitments and Contingencies (Details) € in Millions, $ in Millions		12 Months Ended
	Aug. 04, 2021 EUR (€)	Dec. 31, 2022 USD ($)	Jul. 31, 2018 USD ($)
Other Commitments and Contingencies
Contingent liabilities		$ 0
Zavante Therapeutics
Acquisition of Zavante
Milestone payment receivable prior acquisition			$ 3
Threshold milestone payment that may be settled in ordinary shares			26
Zavante Therapeutics | Maximum
Acquisition of Zavante
Contingent consideration			97.5
Hovione Supply Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cash payments made for amendment of agreement | €	€ 3.2
Threshold aggregate royalty payments | €	4
Acquisition of Zavante
Percentage of annual minimum purchase requirement reduction in 2021		0%
Percentage of annual minimum purchase requirement reduction		0%
Percentage of annual minimum purchase requirement reduction 2022 to 2024		50%
Percentage of annual minimum purchase requirement reduction in 2025		25%
Hovione Supply Agreement | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty payment | €	€ 10
Approval Milestone Payment | Zavante Therapeutics
Acquisition of Zavante
Contingent consideration			25
Net Sales Milestone Payments | Zavante Therapeutics
Acquisition of Zavante
Contingent consideration			$ 72.5

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Millions				12 Months Ended
	Jan. 06, 2023	Jan. 05, 2023	Mar. 11, 2020	Dec. 31, 2022
Subsequent Event
Subsequent Event [Line Items]
Severance and other employee termination-related costs	$ 6
Loan Agreement | Term loan
Subsequent Event [Line Items]
Repayment of debt			$ 30	$ 30
Loan Agreement | Term loan | Subsequent Event
Subsequent Event [Line Items]
Repayment of debt		$ 4.5